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Capripoxviruses are of particular interest as live recombinant vectors for use in the veterinary field, 
since their host-range is restricted to cattle, goats and sheep. The work presented in this thesis is 
a preliminary study undertaken on the South African Neethling vaccine strain of lumpy skin disease 
virus (LSDV). 
As a departure point towards the eventual identification of strong promoter areas in the 143 kb 
genome of LSDV, a portion of its genome was cloned. Three methods for purification of LSDV DNA 
were compared, to determine which yielded the best quality DNA for cloning. DNA extracted directly 
from infected cells was excessively contaminated with bovine host-DNA, complicating the cloning 
of LSDV DNA. The use of pulsed field gel electrophoresis solved the contamination problem, by 
separating viral DNA from bovine DNA. However, insufficient amounts of viral DNA for cloning 
purposes, could be recovered from the gel. Sufficient amounts of good quality LSDV DNA was 
iv 
obtained by extraction from purified virions. Purified LSDV DNA was digested with various restriction 
enzymes to identify those which yielded several 4-1 0 kb fragments, for cloning into the Bluescribe 
plasmid transcription vector. Enrichment for large fragments (8-1 0 kb) was achieved by sucrose 
density centrifugation. Cloned fragments were analysed by Southern blot hybridisation to verify their 
viral origin. Hybridisation studies indicated that several unique regions of the LSDV genome were 
cloned as Pst I and Bam HI fragments respectively, i.e. the cloned fragments contained no 
overlapping regions. In total, 71.25 kb of the DNA of the LSDV Neethling vaccine strain has been 
cloned, representing approximately 50% of the viral genome. The availability of these clones now 
paves the way for further molecular investigations of the LSDV Neethling genome, including 
identification of promoter regions. 
A trial gene, which will be cloned and expressed in LSDV, namely the cloned VPS-gene of 
bluetongue virus serotype 4, was prepared and its nucleotide sequence determined. Homopolymer 
sequences present at the terminal ends of the gene as a result of the original cloning strategy, are 
known to interfere with expression and were removed by means of the polymerase chain reaction 
(PCR). The nucleotide sequence of the resulting PCR-tailored BTV4 VPS-genewas determined and 
used to deduce the amino acid sequence of the protein. The gene is 1638 bp in length and 
encodes a protein of 526 aa. Conserved sequences, 6 bp in length and unique to the 5'- and 3'-
terminal ends of all BTV genes, were detected at the termini of the tailored gene, confirming that 
the original clone was a full-length copy of the gene. Amplification by PCR did not mutate the open 
reading frame (OAF) of the gene, since it was of similar length to that reported for 5 other BTV 
serotypes. 
With a view to future investigations, including the identification of promoter sequences in the LSDV 
genome, a preliminary investigation of LSDV protein synthesis was undertaken, to acquire some 
knowledge of the growth cycle of the virus. Eighteen putative virus-specific proteins were identified 
by radio-labelling infected cells with (358)-methionine. By pulse-labelling infected cells with [35S)-
methionine at various times post infection (p.i.), viral proteins were first detected at 16 hr p.i. It is, 
however, unlikely that the early phase of viral replication commences as late as 16 hr p.i. and these 
results might be attributed to various problems, such as the low multiplicity of infection used and 
that host protein shut-down was inefficient, thus masking the presence viral proteins. 
In conclusion, this investigation resulted in the cloning of 71,25 kb of the LSDV genome, the 
tailoring and sequencing of the BTV4 VPS gene and the identification of 18 putative LSDV proteins. 
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Recent advances in recombinant DNA technology have allowed vaccinologists to enter a new era 
in vaccine development. For many human and veterinary diseases, a vaccine (or an improved one), 
is still needed and may only be developed by the application of the newer biotechnology. These 
diseases include those for which an in vivo produced reagent is undesirable (e.g. infant mouse 
brain extracts), those for which the etiological agent cannot be cultured in vitro and human acquired 
immuno-deficiency syndrome (AIDS). Possible future developments include the following: 
the development of biosynthetic vaccines, defined as formulations containing non-infectious 
protective subunit immunogens that are produced by the use of a biological system. 
the use of non-infectious immunogens in the form of synthetic peptides in vaccines 
employing different micro-organisms as vectors for the delivery and expression of foreign 
antigens to a variety of systems · 
Various recombinant subunit and live vaccines are being investigated to supplement or replace 
vaccines currently being used in the fight against disease. One of the main advantages of live 
versus subunit or dead vaccines is that they may elicit life-long immunity with a single dose. The 
acceptance of recombinant vaccines will depend on evidence of their efficacy and safety. Especially 
if such a vaccine is intended for use in man, then adverse effects must be kept to a minimum. Well 
documented background information on recombinant vaccines is thus essential. 
Lumpy skin disease virus (LSDV), a member of the Poxviridae family, has the potential to be 
developed as a recombinant live vector for veterinary vaccine purposes. At the Onderstepoort 
Veterinary Institute, improved vaccines for the Orbiviruses, including African Horsesickness virus 
(AHSV) and Bluetongue virus (BTV), are being investigated. These are economically important 
pathogens of sheep and horses in many parts of the world. The expression of relevent Orbivirus 
genes in a LSDV vector may offer possible solutions. 
BTV is the prototype of the Orbiviruses, which are members of the Reoviridae family. The genome 
of BTV consists of 10 double stranded RNA segments (Eis and Verwoerd, 1 969), each of which 
encodes a single viral protein (Mertens et a/., 1984; Van Dijk and Huismans, 1988). The virion 
consists of a core of icosahedral symmetry composed of two major proteins (VP3 and VP7) 
enclosing three minor proteins (VP1 ,VP4 and VP6), together with the 10 RNA segments (Verwoerd 
and Huismans, 1 972). This core particle is enclosed by a diffused outer layer, the capsid, which 
consists of polypeptides VP2 and VPS. Three non-structural proteins are also synthesized in 
infected cells, but these are not incorporated into the virion (Huismans, 1979). 
1.2 POTENTIAL ADVANTAGES OF A LIVE RECOMBINANT VACCINE 
The development of live recombinant vaccines which involve viral or bacterial vectors containing 
foreign genes have many potential advantages which make them preferable to subunit vaccines. 
General advantages of a live vaccine include the following: 
it may mobilize different aspects of the immune system (humoral as well as cell-mediated 
immunity). 
it may provide long-term (even life-long) immunity with a single dose. 
there is no need for the addition of carriers, activators or adjuvants. 
since only the essential part of the pathogen is used in the creation of a live recombinant 
vaccine, growth of the pathogen in the host can easily be avoided. 
several genes from various pathogens could be combined in the same vector, making 
vaccination against several diseases possible with a single immunisation. 
once a suitable vector has been developed, the same technology could be applied to other 
vaccines. 
the possible development of heat stable vectors could lengthen the shelf-life of such a 
vaccine. 
Each of these attributes needs to be addressed in research to develop vectors for vaccine 
purposes. 
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1.3 PROFILE OF AN IDEAL LIVE VECTOR 
Any effective vaccine must stimulate a protective immune response, antibody or cell-mediated, 
against the appropriate antigens and offer complete protection for the lifetime of the animal or 
human. An ideal vector used in the preparation of recombinant vaccines must be safe, efficacious 
and easy to manipulate. Furthermore, the host's immune response to the vector must be fully 
understood. 
Major safety issues, especially when considering human vaccines, include the nature of the side 
effects and the risk associated with the immunisation of immuno-difficient or immuno-compromised 
individuals. The live vector should not integrate into the DNA of the host genome and should be 
infectious for the target population only. As far as efficacy is concerned, the vaccine should offer 
long-term protection and induce an effective immunity which would include stimulation of both 
specific T- and 8-cell responses. It should also generate as large a pool of memory cells as 
possible. The optimal route of administration should be explored and evaluation done in the most 
appropriate animal model. 
In constructing stable live vectors, aspects such as high level expression promoters, the most 
convenient insertion sites for stability and DNA-carrying capacity of the vector are to be considered. 
Finally, in order for a new vaccine to be utilized in the field, it would have to be incorporated into 
existing immunisation programmes at low cost and should not interfere with existing vaccines. 
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1.4 AIMS OF THIS INVESTIGATION 
In order to develop a virus as a possible live recombinant vector, considerable knowledge of its 
molecular aspects has to be acquired. Most of the advances in this field have been based upon 
extensive knowledge gained on vaccinia virus (yV) over many years. Because of several drawbacks 
associated with the use of W as a vector (see section 1.6.2), LSDV is considered as a possible 
alternative. 
Very little is however known about the molecular aspects of LSDV. The little that is known, is based 
upon the Kenyan cattle strain which differs from the South African vaccine strain in severity of the 
disease and restriction enzyme sites (see section 1.10.2 and 1.1 o. 7). The South African vaccine 
strain has been in use for over 30 years and field experience has proven it to be both safe and 
effective. 
This is a report of preliminary studies on the molecular biology of the S.A. vaccine strain of LSDV. 
Several lines of investigation have however been undertaken in parallel, rather than pursuing one 
to completion, partly to gain wide methodological experience. 
The aims of this investigation were: 
(a) the preparation and preliminary analysis of LSDV DNA. 
(b) cloning of parts of the genome for future analysis, mapping with restriction enzymes and 
eventual sequencing of regions of importance. 
(c) investigating the time course of viral protein production and viewing the size and time of 
expression of the most abundantly expressed proteins. 
(d) preparation and sequencing of a "trial" gene for insertion into LSDV from a preliminary clone 
of Bluetongue virus serotype 4 segment 5 (BTV4VP5), that encodes the outer capsid protein 
VP5. 
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1.5 GENERAL CHARACTERISTICS OF POXVIRUSES 
These characteristics are based on vaccinia virus as prototypical member of the poxvirus group. 
Table 1.1 Classification of the family Poxviridae * 
I Subfamilies I Genera I Some members I 
Chordopoxviridae Orthopoxvirus Vaccinia, variola 
(vertebrate poxviruses) 
Parapoxvirus Orf 
Avipoxvirus Fowlpox, canary pox 
Capri poxvirus Goatpox, sheeppox, 
lumpy skin disease 





Entomopoxviridae A Melantha melontha 
(insect poxviruses) 
B Amsacta moori 
c Chironimus /uridus 
* Taken from Moss, 1990. 
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1.5.1 Virion structure 
Poxvirus virions are the largest (approximately 300 x 240 x 100 nm in size) and structurally the most 
complex of all animal viruses. Virions have 4 major components : a dumbell-shaped core that 
contains the DNA genome, lateral bodies lying in the concavity of the core, an outer membrane and 
a surrounding envelope (Dales and Pogo, 1981, Fenner eta/., 1987, 1988). 
1.5.2 The poxvirus genome 
The genomic DNA of poxviruses is a very large linear double stranded (ds) molecule which ranges 
in size from 110 kb (parapoxvirus) to 145 kb (capripoxvirus), 165 kb to 210 kb (orthopoxviruses) 
and 280 kb (avipoxviruses). Both ends of poxvirus DNA are covalently closed (Geshelin and Berns, 
. 1974) forming incompletely base-paired hairpin loops at each end of the genome (Baroudy eta/., 
1982). The sequence at the two ends of the genome are identical for about 10 000 bp (Garon et 
a/., 1978), forming inverted terminal repetitions (ITRs). Within vaccinia virus ITRs, 200 bp from each 
end, are tandem repetitions arrayed in adjacent sets (about 1 kb each) that are separated by short 
intervening sequences of about 400 bp each (Wittek et a/., 1978). Hypervariability of the ITRs 
suggests that this region contains most non-essential genes. 
It has been found that the length of the W genome can vary considerably, whilst retaining the 
ability to be replicated or packaged. For example, a viable 9 kb deletion mutant of W has been 
isolated (Panicali et a/., 1983) as well as rabbitpox mutants with even larger deletions (Moyer and 
Roth, 1980). Intact W DNA molecules can be isolated, but the DNA is not infectious (Sam and 
Dumbell, 1981). 
1.5.3 Replication 
DNA replication takes place in the cytoplasm of the host cell, which is unique to poxviruses. The 
poxvirus virion adsorbs and penetrates a cell directly via plasma membrane fusion or indirectly via 
endophagocytosis (Esposito and Murphy, 1989). Once inside the cell, the virion uncoats, which 
causes the core to be released into the cytoplasm. 
Viral cores carry a complete transcription system, that produces early messenger RNA (mANA) 
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during early stages of infection. This includes the viral DNA polymerase and transcription enzymes. 
Soon after infection a shutdown of host-cell protein synthesis then occurs. Poxvirus replication can 
be divided into distinct early and late stages, that flank the peak of DNA replication. During the later 
stages, (when viral DNA has started to accumulate), virion structural protein synthesis takes place 
upon which new virions are assembled. The complete DNA sequence of the W genome and the 
open reading frames it contains, has been determined (Goebel eta/., 1990). A total of 263 potential 
protein-coding regions were then identified. 
1.5.4 Expression of the genome 
Both DNA strands are transcribed via a distinctive RNA polymerase and other RNA-processing 
enzymes (for capping, polyadenylation, etc.) soon after W cores are released into the cytoplasm 
(Esposito and Murphy, 1989). Transcripts can be classified as being early, late and early + late 
relative to viral DNA replication (Moss, 1985). RNA from opposite DNA strands anneal very late in 
infection. 
About half of the genome is expressed before replication starts (Paoletti and Grady, 1977, Boone 
and Moss, 1978) and there appears to be about 1 00 of these early genes distributed throughout 
the length of the DNA (Belle Isle eta/., 1981). Most, if not all W mRNAs are polyadenylated (Nevins 
and Joklik, 1975) and all genes examined thus far have continuous coding segments, with no 
evidence of RNA splicing. 
Following the onset of DNA replication, the late class of genes is expressed and many of the early 
genes are no longer functionally active. Early mRNAs are of relatively uniform size, but the 3' ends 
of late mRNAs are extremely heterogeneous and thus they vary in size. For example, the mRNAs 
for cowpox virus A-type inclusion protein and W structural II kDa protein have variable A-rich leader 
sequences (Berthelet eta/., 1987, Schwer eta/., 1987, Patel and Pickup 1987). Although late genes 
are also distributed throughout the genome, they appear to be concentrated in the central region 
(Belle Isle et a/., 1981). 
Signals for the termination of transcripts at the 3' end of poxvirus open reading frames appear to 
be unevenly spaced tandem I I I I I I NT repeats (Rohrmann eta/., 1986). Transcriptional signals 
(promoters) for RNA polymerases are AT-rich sequences located immediately upstream of coding 
sequences. Consensus TATA and AATA promoter sequences have been identified for several early 
and late W genes (Piucienniczak et a/., 1985). 
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1.6 VACCINIA VIRUS AS A VIRAL VECTOR 
1.6.1 Advantages 
As early as 1796, Jenner discovered that immunisation against the deadly disease smallpox 
(caused by variola virus), could be performed by inoculating uninfected individuals with pustular 
fluid from pox lesions, originating from the teats of cows (Jenner, E., 1798). Successful repetition 
of this practice, originally called cowpoxing, caused the practice to continue for almost 200 years. 
The term vaccination was then proposed and the inoculum became kown as vaccinia virus. 
Vaccinia virus was subsequently used extensively as a vaccine during the WHO Smallpox 
Eradication programme, and as such smallpox became the first and only viral disease to be 
eradicated worldwide. This programme has lead to much experience on the clinical, laboratory and 
epidemiological aspects of vaccine usage as well as gaining extensive knowledge of the virus. The 
vaccine is administered as a single dose which induces relatively long-lived immunity (Henderson 
and Arita, 1985), is simple to manufacture and inexpensive to test and the vaccine is very stable 
(the freeze-dried vaccine can withstand 37°C for 30 days). 
The potential advantages of recombinant vaccinia virus vectors include the fact that they represent 
a live virus infection, which stimulates both humoral and cellular immunity. The virus has a large 
genome (approximately 180 kb) of which significant portions may be deleted without loss of viral 
infectivity. It has been found that at least 25 kb of exogenous DNA can be inserted into vaccinia 
virus (Smith and Moss, 1983). Theoretically it thus has the potential to carry several heterologous 
genes, originating from various disease-causing agents. Such a vaccine would approach the 
ultimate ideal vaccine both for human and veterinary purposes, being able to immunise against 
multiple diseases with a single immunisation, offering life-long protection. 
1.6.2 Disadvantages 
Primary vaccination of humans with vaccinia virus causes a more severe local and general reaction 
than any other live virus vaccine currently in use. In individuals with severe T-cell - or combined 
immuno-deficiencies, progressive vaccinia which is fatal, can occur (Arita and Fenner, 1985). 
Vaccinia virus is also associated with central nervous system complications, notably vaccinia 
encephalitis, which occurs very rarely, but has a high mortality rate. Vaccination of persons with 
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eczema can lead to eczema vaccinatum, but this can be treated with vaccinia- immunoglobulin 
(Arita and Fenner, 1985). 
If vectored vaccinia virus vaccines are to be introduced for human use, a substantial reduction of 
adverse effects could be achieved with appropriate prevaccination screening (Esposito and Murphy, 
1989). The vector strains may well be less virulent than those originally used for vaccination. 
Veterinary use of vectored vaccinia virus vaccines would involve a minimal risk of adverse effects 
in humans. The principal risk would be the accidental inoculation of vaccinators and other animal 
handlers. Still, this would be of little consequence if vaccinators were prescreened and vaccinated 
accordingly. 
1. 7 POXVIRUS VECTOR CONSTRUCTION 
1. 7.1 Gene transfer by marker rescue 
Because of the large size of the poxvirus genome, genetic recombination using DNA ligation is not 
possible. The non-infectious nature of the DNA also prevents its propagation by transfection of 
uninfected cells. These difficulties had to be overcome in order to develop W as an infectious 
recombinant vectored virus. Genetic recombination studies, which involved gene transfer by marker 
rescue (Sam and Dumbell, 1981), led directly to the discovery that foreign genes can be inserted 
in the poxvirus genome by homologous DNA recombination (Mackett et a/., 1982). 
Genetic recombination studies were first done by co-inoculation of two inactivated poxviruses into 
animals or cell cultures (Fenner, 1970, 1979). This involved rescue of a protein- inactivated poxvirus 
by a poxvirus in which the DNA was inactivated (see Fig. 1.1 A). 
In 1981, Sam and Dumbell reported the recovery of rabbitpox virus when its DNA was transfected 
into ectromelia virus-infected cells. Also, when they transfected DNA restriction fragments of the 
rabbitpox strain of W into cells already infected with a phenotypically different W, recombinants 
with both rabbitpox and W phenotypic markers were recovered (see Fig. 1.1 B and C). Several 
reports which confirmed and extended this concept, followed when Condit et a/., 1983, 
Nakano et a/., 1982 and Weir et a/., 1982 identified physical loci of temperature sensitive (ts) 
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Steps in the historical development of the use of vaccinia virus as an expression vector for 
heterologous DNA sequences. 
(A) Demonstration of recombination between vaccinia and ectromelia viruses by CO·infecting cells 
with both viruses producing vaccinia, ectromelia and recombinant viruses. (B) Rescue of vaccinia 
virus genome in cells transfected with intact W DNA and infected with ectromelia virus or 
temperature-sensitive mutants of W to produce vaccinia, ectromelia and recombinant viruses. (C) 
Marker rescue of fragment of W DNA by homologous DNA recombination in cells transfected with 
W fragment (marker+ DNA) and infected with marker" virus. (D) Targeted insertion of heterologous 
coding sequences into W genome by homologous DNA recombination. Chimeric plasmid DNA (a) 
that contains W DNA flanking the heterologous DNA (2) is transfected into cells already infected 
with W. W regulatory elements (1), W transcript termination elements (3). (Taken from Esposito 
and Murphy, 1989.) 
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The first infectious vectored W recombinants were subsequently produced by Panicali and Paoletti, 
(1982) and Mackett et a/., 1982 when they developed methods for inserting heterologous coding 
sequences into W by homologous recombination. 
1. 7.2 Construction of a recombinant vaccinia virus vector 
Two approaches for the expression of foreign genes in W have been developed. The first consists 
of inserting foreign DNA into available r.e. sites within non-essential regions of the W genome 
(Panicali and Paoletti, 1982). Although the method is technically simple, the procedure limits the 
promoters used, since the foreign DNA is under control of the non-essential genes promoter. This 
promoter might not necessarily result in optimal expression of the gene. This method can also lead 
to the formation of fusion proteins with unpredictable properties. 
The more commonly used method involves the translocation of defined W promoters to a special 
plasmid vector (insertion vector) and lends itself to optimisation of expression, the synthesis of 
authentic or fusion proteins and the development of a general expression vector system. 
For the latter procedure, Mackett eta/., 1982 have constructed W recombinants expressing foreign 
genes in a two-stage process (Fig. 1.2). Firstly, a series of insertion vectors that contains a chimeric 
gene flanked by W DNA, was constructed. The chimeric gene consisted of a W promoter region, 
(including the transcriptional start site and upstream regulatory sequences), and genetically 
engineered restriction endonuclease sites for introduction of the foreign DNA The flanking W DNA 
determines the site at which foreign DNA is inserted in the viral genome. To preserve the infectivity 
of the virus, the foreign gene must be inserted into a region of the genome that is not essential for 
viral growth. Several non-essential regions have been identified of which the thymidine kinase (TK) 
gene, is often used. 
In the next stage, the chimeric gene is inserted into W. This is achieved by transfection of wild-type 
virus infected cells with the insertion vector. Homologous recombination occurs between the W 
sequences flanking the chimeric gene and the viral genome, thus producing a recombinant virus. 
The foreign DNA segments that have been introduced, typically have their natural initiation and 
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Insertion of heterologous DNA coding sequences into W by insertional inactivation of the virus 
thymidine kinase (TK) gene. A chimeric plasmid is constructed in such a way that the coding 
sequences are inserted downstream of a W transcription site that follows W promotor sequences; 
this casette interrupts coding sequences for the W TK gene. Cells already infected with W are 
transfected with the chimeric plasmid before the peak of viral DNA replication. The infection is then 
allowed to proceed to completion. Three types of progeny virus are produced: wild-type TK+, 
spontaneous TK" mutants and TK" recombinants. TK" viruses are isolated by plaque purification 
using TK- cells that are maintained in overlay medium containing BUdR. Recombinants are then 
differentiated from spontaneous mutants by hybridisation and immunological methods using cells 
infected with virus from individual virus plaques. (Taken from Mackett eta! .. 1985). 
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Both the level and regulation of expression of the foreign gene are determined by the promoter 
used. These promoters can be classified as being early, early/late and late according to the interval 
post infection, during which a specific gene is expressed. Genes that are controlled by early/late 
promoters, are expressed throughout an infection and one such promoter, the P7.5 promoter, is 
commonly used to drive the expression of foreign genes. 
1. 7.3 Selection of recombinants 
With the standard CaCI2-transfection method, only a small percentage (about 0.1 %) of virus progeny 
will be recombinants. A method of selection or screening between wild and recombinant viruses 
is therefore essential. Various ways of selection have been developed, e.g. plaque hybridisation 
(Panicali et a!., 1983), thymidine kinase (TK)-negative selection (Mackett et a/., 1982) and 
.a-galactosidase expression (Chakrabarki et a/., 1985). Of these; TK-negative selection has been 
widely used and is based on the fact that insertion of foreign DNA into the TK-gene, results in loss 
of TK-activity which can be positively selected for. Disadvantages of this method, however, include 
requirements for: 
(i) special TK-negative W susceptable cell lines to be used 
(ii) the use of a mutagenic selective agent, 5-bromo-deoxi-uridine (BUdR) 
In addition, spontaneous TK-mutants arise at a high frequency, necessitating additional steps to 
distinguish them from recombinants. 
Franke et a/., 1985, developed a method using the neomycin resistance gene as a dominant 
selectable marker. A further dominant one-step plaque selection system was developed by Falkner 
and Moss (1988), based on expression of the E. coli xanthine-guanine phosphoribosyl transferase 
(gpt) gene. Mycophenolic acid (MPA), an inhibitor of purine metabolism, reversibly blocks formation 
of W plaques on a variety of cell lines. This inhibition is overcome by co-expression of the foreign 
gene and gpt-gene and the addition of xanthine and hypoxanthine to the medium. Synthesis of 
xanthine-guanine phosphoribosyl transferase enables only recombinant viruses to form plaques in 
the selective medium. 
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1.8 EXAMPLES OF VECTORED VACCINIA VIRUS EXPERIMENTAL VETERINARY VACCINES 
1.8.1 Vaccinia : rabies vaccine 
A vaccinia-rabies recombinant (V-RG) in which the surface spike glycoprotein (G) gene of the ERA 
strain of rabies virus was expressed after insertion into the TK region of Copenhagen W, was first 
constructed by Kieny and coworkers (1984). Mice, rabbits (Wiktor eta/ .. , 1984), skunks (Tolson et 
a/., 1987), raccoons (Rupprecht et a/., 1986) and foxes (Biancou et a/., 1986) inoculated 
intradermally with the recombinant produced neutralisi.ng antibodies and were protected against 
lethal rabies virus challenge. In addition, raccoons and foxes were fully" protected via the oral 
vaccination route. 
Safety trials in numerous wild animal species have been carried out: none of these indicated that 
V-AG was pathogenic (Artois et a/. 1990) although limited horizontal transmission occurred from 
vaccinated animals (Rupprecht et a/. 1988). In 1987 a field trial was carried out in Belgium in a 
restricted military zone to test V-AG placed in an oral bait, namely chicken heads (Pastoret eta/., 
1988). No indication of a vaccinia virus infection was found in animals which had taken the baits. 
Since that trial, the V-RG vaccine has been used in a manufactured bait in more extensive areas 
of Belgium (Brochier et at., 1991) and in Northern France. 
In the USA, where raccoons and skunks are important carriers of the disease, field trials were first 
carried out on Parramor Island, off the coast of Virginia. Permission has recently been granted to 
carry out field trials in Pennsylvania. The main rabies threat in South Africa is the domestic dog and 
similar approaches are currently being investigated for oral vacci"nation with recombinants in this 
area. 
1.8.2 Vaccinia : Venezuelan equine encephalitis NEE) vaccine 
Kinney and colleagues (1989) produced W recombinants expressing the 26S polygene of VEE, 
which was normally cleaved to form all of the virion structural proteins. lntradermally inoculated mice 
developed VEE virus neutralising antibodies and were protected against an otherwise lethal 
challenge with virulent virus. The recombinants were as effective as the attenuated-live virus vaccine 
in inducing cross-protection against challenge with subtypes of VEE virus isolated from outbreaks. 
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These recombinants are.·now being developed as candidate vaccines. 
1.8.3 Vaccinia : rinderpest vaccine 
Rinderpest virus (RPV) is a member of the morbillivirus group and is considered to be one of the 
most economically important diseases of cattle in Africa, the Middle East and Asia. Because 
morbilliviruses have a negative sense RNA as genome, W recombinants that carry a DNA copy 
(eDNA) of the mANA for a protein (which plays an important role in protection), the F protein, were 
constructed (Barett eta/., 1989). The F protein was correctly expressed and processed in vitro and 
recombinants were able to elicit RPV neutralising antibodies in intradermally inoculated rabbits. 
These rabbits were also protected against lethal challenge with RPV. An experiment in which a 
number of cattle were inoculated with the RPV-F protein recombinant W followed soon (Belsham 
et a/., 1989) and in this case, all cattle challenged were also protected. Non-vaccinated control 
animals developed acute rinderpest and died within 8 days after challenge. 
1.9 EXTENSION TO HOST-RANGE RESTRICTED POXVIRUSES 
Complications associated with the use of W (see section 1.6.2) are for many sufficiently severe to 
argue against the widespread use of W recombinants as human as well as veterinary vaccines. 
For veterinary purposes, the risks involve the animal handler, rather than the animal to be 
vaccinated. In light of this view, an alternative approach which allows the utilization of much 
experience gained with W, is being investigated. This is the development of those poxviuses which 
have host-ranges that are restricted to particular target animal groups and are therefore not capable 
of replicating and causing disease in humans. 
One of these, fowlpox virus (FPV), which is limited to avian species, has been exploited to express 
a variety of genes. Taylor eta/. (1988a) were the first to develop a FPV recombinant expressing the 
haemaglutinin molecule from a highly virulent avian influenza virus. On immunisation of chickens 
and turkeys, the recombinant offered protection against a lethal challenge with either the 
homologous or a heterologous influenza virus strain. A strain of the Newcastle disease virus (NDV) 
has been expressed in the same way (Boursnell et a/. 1990) and although low levels of antibody 
was induced, protection in chickens could be demonstrated. 
15 
The fact that FPV has been reported to induce a cytotoxic effect not associated with the production 
of infectious progeny virus in human amnion cells (Burnett eta/., 1968), led to experiments in which 
the rabies virus glycoprotein was expressed under the control of a W promoter, using FPV as a 
vector (Taylor eta/. 1988b), in non-avian species. The level of rabies glycoprotein expression was 
sufficient to induce a specific immune response in mice, cats and dogs, and the immune response 
was protective against a live rabies virus challenge. 
No evidence could be found that either the parental FPV strain or the recombinant, could induce 
productive infection in non-avians. This ability provides a built-in safety feature in vaccination 
procedures, since the potential for transmission to other species or to non-vaccinated individuals 
would be greatly reduced. The use of FPV as a non-replicating vector may also be indicated in 
immuno-compromised individuals, who might otherwise be susceptible to generalized infection by 
a replicating vector (Taylor eta/., 1988b). This concept was extended to another avipox virus with 
the construction of a canarypox-rabies recombinant virus (Taylor et a/., 1991), which was 
significantly better at eliciting neutral ising antibodies and was about 1 00 times more effective in 
protecting dogs and cats against lethal rabies challenge than the FPV recombinant. 
Swinepox virus (SPV), another poxvirus with limited host-range, is also under investigation as a 
species-specific recombinant vaccine vector. The clinical presentation is that of a mild, self-limiting 
infection with lesions detected only in the skin and regional lymph nodes. Investigation to the 
physical, molecular and biological characterization of the virus and development within the host has 
begun (Massung and Moyer, 1991 a and b) and the TK-gene has been isolated (Feller eta/., 1991 ). 
1.10 LUMPY SKIN DISEASE VIRUS (LSDV) 
1.1 0.1 Introduction 
The promising results in the research of FPV and SPV have prompted interest in the development 
of Capripoxviruses, of which lumpy skin disease virus (LSDV) is a member, as potential host-range 
restricted poxvirus vectors. Capripox virus growth is limited to sheep, goats and cattle in those 
areas of the world where poxvirus diseases of these animals are endemic (Africa, Middle East and 
Asia). 
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1.1 0.2 History 
Lumpy skin disease is an acute, subacute or inapparent viral disease of cattle. Other members of 
the Capripox genus cause sheeppox and goatpox. Lumpy skin disease (LSD) was first described 
in Northern Rhodesia (Zc:i'mbia) in 1929 (MacDonald, 1931 ), after which it spread to Bechuanaland 
(Botswana) in 1 943 (Von Backstrom, 1 945) and reached South Africa towards the end of 1 944 
(Thomas and Mare, 1945), causing a severe outbreak. It was estimated that 75% of the cattle 
population in South Africa was affected, with up to 75% mortality on some infected premises. 
Sporadic outbreaks of the disease have recurred since that time. 
In 1957, LSD reached epidemic proportions in Kenya (MacOwen, 1 959), where the disease was 
relatively mild with only 1 0 LSD associated deaths. The LSD outbreak was associated with an 
outbreak of sheeppox in indigenous fat-tailed sheep. Experiments in which sheep injected with a 
Kenyan strain of LSDV (Londiani) and cattle injected with a sheeppox strain both developed skin 
lesions, led to the suggestion that sheep might possibly act as carriers of LSDV (Capstick, 1 959). 
Capstick and Coakley (1 961) showed that cattle could be immunised against LSD using a Kenyan 
strain, Kedong of sheeppox virus. In South Africa, Capripox has never been reported in sheep or 
goats, although they are kept in close contact with cattle. In other parts of the world, e.g. 
Bangladesh, India, Yemen and the Middle East, sheeppox and goatpox are the prevalent 
Capripoxviruses. 
Successful vaccination with a live LSD virus is practised in Kenya and South Africa and vaccinated 
animals have a life-long immunity. A live vaccine based on the Kedong strain of sheeppox (Capstick 
and Coackley, 1 961) has been commercially produced in Kenya for immunisation of sheep, goats 
and cattle. A local reaction occurs at the site of injection in 1 0% of cases but produces no ill effects 
on general health or production. Although no excretion of virus from vaccinated cattle is thought 
to occur it is generally considered wise to use the vaccine only in sheeppox endemic areas (Davies 
and Otema, 1 981). An attenuated vaccine for use in sheep and goats, based on the sheep isolate 
0240, has also been developed (Kitching eta/., 1 987). 
In South Africa, the Neethling strain of LSDV has been attenuated for vaccine purposes by first 
passaging it in embryonated eggs (20 passages), after which it was adapted to tissue culture. 
Since the 1960's it has been produced routinely in tissue culture (Weiss, 1 968) and used as a 
vaccine. Approximately 50% of vaccinated cattle show a reaction at the injection site and a temporal 
fall in milk production may occur. Following vaccination, some cattle have no detectable antibody, 
but still become immune. Calves from vaccinated cows have a colostrum derived passive immunity 
which persists for six months (Weiss, 1968). This may interfere with efficient vaccination of calves 
less than six months old. No cases of LSD were reported in South Africa during a 15 year period 
ranging from 1975-1989. However, in 1990 a serious outbreak occured which soon spread 
throughout the whole of Africa. Lumpy skin disease has not yet been eradicated from any country 
in which it has appeared. 
1.1 0.3 Epidemiology and transmission 
Epidemics of LSD have been associated with the rainy season and locations (along water sources) 
suggested transmission in cattle by insect bite. The virus has been recovered from the flies 
Stomoxys calcitrans and Biomyia fasciata (Kitching and Mellor, 1986). The virus may be transmitted 
directly or indirectly throu.gh water contaminated with infective saliva (Weiss 1968). 
1.1 0.4 Clinical signs 
The initial clinical signs of cattle naturally infected with lumpy skin disease virus are lachrymation, 
salivation, loss of appetite, nasal discharge and a febrile response following an incubation period 
of 2 to 5 weeks. Eruption of circumscribed, firm, round and raised nodules (0.5 to Scm in diameter) 
occurs in the skin that may involve the entire body, within 48 hours of the first rise in temperature 
(Weiss, 1968). Soft, yellowish-grey nodules may appear in the mucous membranes of the mouth, 
nose, vulva and prepuce which give rise to erosions and ulcers. In addition, lymphadenitis, 
especially of the prescapular, precrural and subperotid, is aiways observed. The nodules usually 
undergo complete necroses and form ulcers. The overlaying exudate becomes inspisated and the 
dried scabs which are formed are shed in 3 to 5 weeks. Healing is slow, as the focal inflammatory 
reaction may persist for several months and then complete scars are left. 
Although the mortality rate is low (less than one to ten percent), the disease is of major economic 
importance through indirect losses resulting from emaciation, temporal or permanent cessation of 
milk production in lactating cows (Weiss, 1968), infertility in bulls and permanent damage to hides, 
which affects the quality of the leather (Green, 1959). Recovered animals develop a life-long 
immunity and are resistant to re-infection. Their sera contain neutralising antibodies which persists 
for at least 5 years (Wei~s. 1968). Passive immunity acquired by calves through colostrum may 
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persist for 6 months. 
1.1 0.5 Propagation of LSDV 
LSDV replicates in a variety of cell cultures, including lamb and calf kidney, adrenal, testes, calf 
muscle, rabbit fetal kidney and baby hamster kidney cells (Prydie and Coackley, 1959). The cells 
most frequently used for isolation are primary lamb testis (L T), lamb kidney (LK), calf kidney and 
calf testicle cells. LSDV also replicates in embryonating chicken eggs without producing remarkable 
lesions (Van Rooyen eta/., 1959). 
1.1 0.6 Antigenic relationship between strains of Capripoxviruses 
Although the Capripoxviruses are classified according to whether they cause clinical disease in 
sheep, goats or cattle, most strains do not have absolute host specificity (Capstick 1959, Kitching 
and Taylor, 1985). The majority of those examined did however, show a preference for growth in 
either sheep, goats or cattle. Strains also varied in their pathogenicity in different species and 
different breeds. 
Serological as well as cross-protection studies indicated a close antigenic relationship between 
isolates from all three host species. Direct and indirect fluorescent antibody and serum 
neutralisation tests could not distinguish the viruses of LSD and Kenya sheep-and goatpox from 
each other or from sheeppox and goatpox strains from the Middle East (Davies and Otema, 1981 ). 
Results of cross-neutralisation tests (Kitching and Taylor, 1985) showed that immune serum from 
Yemen, India and Nigeria isolates of sheeppox and goatpox were equally effective in neutralising 
homologous and heterologous strains. These results provided support to the suggestion that 
distinction between sheeppox and goatpox solely on clinical grounds can not be justified. 
Another confirmation of the close antigenic relationship was demonstrated by cross-protection 
between isolates of capripoxvirus, provided by passive immunisation or colostral antibody (Kitching, 
1986). Sheep were protected against a virulent Nigerian isolate of sheeppox virus using serum 
against Yemen goatpox and against virulent Yemen goatpox using serum against Oman sheeppox. 
Lambs born to ewes hyperimmunised with different isolates of capripox were protected against 
challenge with Yemen goatpox. 
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Kitching et a/., 1986 labelled proteins from various isolates of sheeppox, goatpox, sheep-and 
goatpox and LSD (Neethling) viruses with [35S] Methionine to show that the major structural 
polypeptides of those viruses co-migrated on polyacrylamide gels. The agar gel immunodiffusion 
test with radiolabelled antigen preparations was used to identify a major common precipitating 
antigen of 67 kDa, but could not distinguish between the different members of the capripoxvirus 
group. 
1.1 0. 7 Genomic organization and relationship between isolates 
1.1 0.7.1 Restriction enzyme analysis 
Different isolates of Capripoxvirus have similar linear DNA genomes of between 143 and 147 kb in 
length as calculated by summation of the lengths of fragments yielded by the Hind Ill restriction 
enzyme (Gershon and Black, 1988). 
Restriction enzyme analyses have been used to compare the relatedness of genomes of different 
Capripoxviruses (Black eta/., 1986). In the first study, the DNA of 12 isolates was digested with 
Hind Ill and the patterns of fragments generated analysed by agarose gel electrophoresis. It was 
shown that there is a close degree of similarity between restriction patterns of isolates regardless 
of animal origin. Based on calculations of Schumperli eta/., 1977, Black eta/., 1986 concluded that 
the genome homology of the Capripoxviruses must be greater than 80%. Isolates from different 
animal species did however, have specific differences in their patterns, so that a sheeppox group 
and a goatpox group could be distinguished. 
The extension to maps of other restriction enzymes, notably Ava I and Sail, demonstrated that the 
genome of the Kenya cattle isolate KC-1 does not posess a high degree of nucleotide sequence 
homology with genomes of either Orthopox-, Parapox-, Leporipox- or African swine fever viruses 
(Gershon and Black, 1987). 
The degree of nucleotide sequence divergence between the genomes of typical sheep, goat and 
cattle isolates was calculated from numbers of conserved and non-conserved Hind Ill, Pst I, Ava 
I and Sail sites (Gershon and Black, 1988). The three groups were calculated to be between 95.8% 
and 97% homologous at nucleotide sequence level. The comparisons demonstrated that the typical 
cattle and sheep isolates.were more closely related to each other than either was to the typical goat 
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isolate. This in turn indicated that the sheep and cattle isolates diverged from the goat isolate prior 
to diverging from one another. The genomes of cattle isolates KC-1 and South African cattle (SAC-1) 
were found to be closely related, but differed at two Hind Ill sites. Evidence suggested that isolates 
could arise from recombination between goat-type and cattle-type genomes (Gershon and Black, 
1988). 
Restriction enzyme maps demonstrated that relatively small deletions are present on genomes 
when compared to one another (Gershon and Black, 1988) and these deletions are not confined 
to the terminal or near-terminal regions of the genome. By analogy to the Orthopoxvirus genome, 
host-range genes would be expected to be located near the terminal regions. This data led to their 
suggestion that the stability of Capripox genomes are related to a more restricted set of genes 
responsible for host-range (Gershon and Black, 1988). 
1.10.7.2 Terminally repeated regions 
As is common to other poxviruses the capripox genome processes terminally repeated regions 
(Gershon and Black, 1987, Gershon and Black, 1988). These regions were found to be 1.13 kb -
6.23 kb in length in the cattle isolate KC-1 (Gershon and Black, 1987). By mapping various r.e. sites 
present within the terminal 1 0 kb of the genome of the Indian sheep isolate lng-1, the terminal 
repeats were shown to be between 2.25 kb and 3.40 kb in length and inverted with respect to one 
another (Gershon and Black, 1988). 
1.10.7.3 Non-essential regions 
For the development of Capripox as a live recombinant vector, non-essential regions into which 
foreign genes could be inserted, have to be identified. Four such regions from the isolate KS-1, 
namely the TK-gene, the CT3C region, CT4 region and 02 region, have already been identified 
(Bostock, 1990). 
The TK-gene (OAF CF8) is contained within the S fragment produce by digestion of the DNA of the 
KS-1 isolate with Hind IlL Two other complete OAFs, namely CF7 and CF8a and two incomplete 
OAFs, namely CF6 and CF9, have been identified in this fragment (Fig. 1.3). 
Sequencing data have shown that the TK-gene and OAFs CF6, CF7 and CF9 are homologous to 
4 contiguous OAFs from the central region of W DNA (Gershon and Black, 1989). They also match 
21 
four OAFs found in the FPV genome. The other complete OAF, CF8a, has no homologue in W or 
FPV DNA, but is homologous to a region downstream of the TK-gene of Shope Fibroma virus (SFV) 
DNA. The Orthopox-, Leporipox-, Avipox- and Capripoxviruses thus posess genes in common and 
there is a resemblance in terms of genetic organisation. 
The nucleotide sequence also revealed that the S fragment is more A + T rich than the equivalent 
regions of W, SFV and FPV (Gershon and Black, 1989). A high A + T content for the whole 
genome of the capripox isolate KS-1 is indicated by the relatively high frequency of A+ T-rich r.e. 
sites, such as Dra I (TTTAAA) and Hind Ill (AAGCTT) and relatively low frequency of G + C-rich 
sites, such as those for Pst I (CTGCAG) and Sal I (GTCGAC) (Gershon and Black, 1987). 
1.1 0. 7.4 LSDV recombinants 
Aecombinational plasmids (analogous to those described for VV), which each contain one of the 
above mentioned non-essential capripox region and the W P7.5 promoter, have been constructed 
(Bostock, 1990). Experiments are in progress to make Capripoxvirus recombinants carrying and 
expressing the F protein gene of the rinderpest virus. Construction of a Capripox virus expressing 
the 67 kDa surface antigen (p67) of Theileria parva sporozoites has also been reported (Juarrero 
eta/., 1991). This was achieved by heterologous recombination of theW TK-gene with the capripox 
TK gene. The recombinant plasmid vector used contained the gene coding for p67 under regulatory 
control of the P7.5 promoter of W. The E. coli gpt gene was used as a selective marker upon 
which recombinants were selected in the presence of mycophenolic acid. Expression of the p67 
antigen was confirmed in Western blot analysis. The capacity of the recombinant to immunise 
against T. parva is currently being evaluated. 
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Figure 1.3 
The Hind Ill restriction enzyme map of the KC-1 isolate of capripoxvirus. The individual fragments 
are assigned letters according to decreasing size. Above the map is shown an expanded region 
covering the S fragment which contains the non-essential TK gene (CF8 TK) and below is an 
enlarged map of the terminal regions which contain the CT3C and CT4 non-essential regions. The 
02 non-essential region is black. (Bostock, 1 990). 
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1.11 OTHER VIRUSES CONSIDERED AS LIVE VECTORS 
1.11.1 Adenoviruses 
The current human adenovirus vaccine protects against acute respiratory disease and has been 
administred to several million USA soldiers without significant complications. It consists of two non-
attenuated strains, types 4 and 7 and is given orally as a gelatin-coated tablet from which the virus 
is released after passage through the stomach. The virus then replicates in intestinal cells and 
induces effective immunity without causing the disease. 
Recombinant adenovirus vaccines would offer the following advantages: they would have a low 
cost, would not require purification or be pyrogenic, they could be administred orally and induce 
immune response at the mucosal surface and they would have a narrow specific host range {WHO 
meeting, 1989). The small ds DNA genome (36 kb) of the virus however, places limitations on the 
amount of foreign DNA that may be inserted. 
The hepatitis B virus surface antigen (HBsAg) was the first antigen to be inserted into a 
non-essential region, E3, of the viral genome by homologous recombination (Morin et a/., 1987). 
The recombinants were tested in hamsters where they evoked antibodies to both adenovirus and 
HBsAg and when inoculated intravenously into chimpanzees, produced partial protection against 
challenge (Lubeck eta/., 1989). Recombinant adenovirus vaccines, containing the structural genes 
env, gag and the regulatory protein rev, directed against HIV have also been developed (Chanda 
et a/., 1990). The HIV envelope sequences were biologically active, as they bound to the CD4 
receptor, but the level of expression was low. 
Although the prospect of having vaccines that could be administered orally is exciting, the limited 
heterologous gene carrying capacity of adenoviruses, their nuclear site of DNA replication, their 
mANA splicing capacity, their ability to cause transformation in cell cultures and tumors in animals 
(Graham, 1984) and their persistence in lymphoid tissues represent unanswered concerns. 
Furthermore, no data is also available on safety in children or immuno-compromised individuals. 
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1.11.2 Herpesviruses 
In general, herpesviruses evoke very strong cell-mediated immune responses as well as strong and 
long-lasting humoral responses (Esposito and Murphy, 1989). Additionally, the viruses have rather 
narrow specific host ranges, which is considered advantageous in any live virus vaccine. Particular 
herpesviruses are also associated with neurological and neoplastic diseases however, and all 
herpesviruses are associated with persistent infection and life-long carriage. These characteristics, 
unless further defined and absolutely controlled, would be considered unacceptable in any live virus 
vaccine. 
Herpes simplex virus (HSV) has been used successfully as a vector for expressing hepatitis B 
surface antigen (Shih eta/., 1984) and for Epstein Barr virus nuclear antigen I (Hummel eta/., 1986). 
Unique prototype herpes simplex virus vectors have been developed (Meigner et a/. 1988) which 
consist of HSV type I virus from which 15% of the genome has been deleted and into which genes 
for HSV type 2 virus immunogenic proteins have been inserted. Because of the extend of the 
deletions, these viruses have genomic space for the insertion of more than 1 o kb of heterologous 
DNA. Safety and immunogenicity of these recombinants have been examined. These recombinants 
do not disseminate from the site of inoculation, nor do they cause systemic infection and 
neurovirulence has been eliminated. Both recombinants have been shown to protect mice, guinea 
pigs, rabbits and 2 species of primates against challenge with wild- type HSV type 1 and 2 viruses. 
These viruses could be considered as human vectored vaccines against several diseases. 
1.12 LIVE BACTERIAL VECTORS 
1.12.1 Introduction 
Traditionally, bacterial vaccines have been either inactivated toxins such as tetanus toxoid or 
whole-cell vaccines such as the pertussis vaccine, which proved to be highly effective. However, 
for many bacterial pathogens, killed preparations provide only short-term immunity and low efficacy 
(Dougan eta/. 1989). Subunit vaccines do not generally stimulate strong cellular immunity, but if 
living organisms persist in particular tissues of the host, high cellular immunity is achieved. (Collins 
and Mackaness, 1968). 
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Pathogenic bacteria can be attenuated by mutations which prevent their virulence, but do not 
influence their ability to induce a protective immune response. Bacteria can be genetically 
engineered to express foreign antigens, which opens up the possibility of devising multivalent live 
bacterial vaccines. Because bacteria can be controlled with antibiotics, adverse effects in 
immuno-supressed subjects are not such a critical issue as it would be in virus-vectored vaccines 
(WHO meeting, 1 989). 
1.12.2 Salmonella 
Salmonella is a facultative intracellular pathogen, therefore cell-mediated immunity is more important 
than humoral immunity in resistance to the disease, salmonellosis (Fields et a/. 1 986, Dougan et 
a/. 1 987). For this reason, many investigators have considered the possible use of attenuated 
Salmonella for the expression of foreign antigens. 
A galactose epimerase (gal E) mutant of S. typhi, designated TY21 a, has been constructed by 
Germanier and Furer (1 975) and is used extensively as a vaccine for the prevention of typhoid 
fever. Extensive evaluation in humans has proven it to be extremely safe (Gilman eta/., 1 977). In 
theory, it should be possible to express protective antigens from any pathogen in Salmonella 
vaccine strains and thus deliver heterologous antigens to the immune system (Dougan eta/. 1 987). 
Formal eta/. (1 981) were the first to use Salmonella as a multivalent vaccine by introducing Shigella 
sonnei antigens into Ty21 a. Ty21 a has also been used as a vector for the expression of cholera 
(Clements and EI-Morshidy, 1 984) and enterotoxigenic E. coli (Stevenson and Manning, 1985, 
Dougan et a/. 1 986). 
The genetic strategy used for Salmonella vectors is expression of the heterologous antigens from 
genes encoded on recombinant plasmids introduced as extrachromosomal DNA into the vaccine 
strains. Some plasmid constructs however, are lost once antibiotic selective pressure is relieved in 
vivo (O'Callaghan et a/. 1 988) The cloned sequences may also undergo deletion or other 
rearrangements. In order to stabilize the expression of antigens in vivo, Strugnell and his colleagues 
1990, integrated the heterologous gene into the Salmonella chromosome. They constructed a 
chromosomal integration vector consisting of an antibiotic resistance gene, the aro C gene into 
which the foreign DNA can be cloned and on either side of it, flanking S. typhimurium DNA. The 
flanking regions are thell used to integrate the foreign DNA into the Salmonella chromosome 
utilising homologous recombination. 
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Despite its impressive safety record and proven efficacy, the use of Salmonella Ty21 a strain suffers 
from several drawbacks: it grows slowly and transforms and recombines less well than the parent 
strain. Multiple doses are needed to achieve 60- 70% protection (Hirschel eta/., 1985) Initial trials 
of the attenuated S.typhi constructs, expressing the 0 antigen of S. sonnei (Black eta/., 1987) and 
the 0 antigen of Vibrio cholera were only partially successful. 
Ty21 a expressing S. sonnei antigen was safe and immunogenic when given to North American 
volunteers. The initial lyophilised vaccine lots conferred significant protection against dysentry. 
However, subsequent lots failed to protect significantly (Black eta/., 1987). Even a manufacturing 
protocol specifically designed to preserve flagellar structure (which was found to differ in the initial 
and subsequent lots), did not improve the efficacy of the bivalent vaccine (Herrington eta/., 1990). 
Although Ty21 a expressing V. cholerae lnaba 0 antigen elicited strong anti- S.typhi and modest 
anti-lnaba serological responses, diarrhoea still occurred in most of the vaccinated candidates after 
challenge with V.cholerae. Flynn and colleagues (1990) were the first to demonstrate that cytotoxic 
T-cells can also be elicited against a specific foreign antigen (of Plasmodium yoellt) expressed in 
Salmonella (Flynn et at., 1990). Although Salmonella has great potential, further research is needed 
in order to develop it as a bacterial vectored vaccine. 
1.12.3 Bacillus Calmette-Guerin 
The most widely used vaccine against tuberculosis is the live bacterial vaccine BCG (Bacillus 
Calmette-Guerin), which is an avirulent derivative of Mycobacterium bovis. Distinct advantages of 
using BCG as a vector for expression of foreign antigens include the facts that the vaccine has 
superb adjuvant activity, being able to induce both humoral and cell-mediated immunity, and has 
been administered to billions of people within the first months of life with remarkably few side effects 
(Lotte et at., 1984). The bacterial genome can also accommodate substantial amounts of additional 
DNA 
A host-vector system of BCG, which is a fundamental aspect of the development of recombinant 
live BCG vaccines, has recently received increased attention (Jacobs et a/., 1987). Random 
fragments of a ds DNA bacteriophage from M. smegmatis were cloned into a cosmid vector and 
the recombinants used to transfect M. smegmatis to generate viable phage (called phasmids, 
because they were composites of functional plasmid and phage DNA). The phasmid DNA was used 
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successfully to infect several strains of BCG. 
Matsuo and colleagues (1 990) were the first to report the expression and secretion of a foreign 
human immuno-deficiency virus (HIV-1) antigen from BCG. With the help of E. coli -mycobacteria 
shuttle vectors, they constructed secretion vectors in which an extracellular a-antigen of 
Mycobacterium kansassi was utilized as a carrier. The epitope of HIV-1 antigen was effectively 
secreted from BCG using this system, and could be used widely to secrete other foreign antigens. 
It remains to be determined whether expressed antigens will be effective in eliciting substantial 
immunity and protection. BCG is not a vector to be used in cattle, however, since herds are 
routinely tested for tuberculine infectivity. Its use in cattle would therefore result in false positive 
signals upon testing. 
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CHAPTER TWO 
ISOLATION AND CLONING OF LUMPY SKIN DISEASE VIRAL DNA 
2.1 INTRODUCTION 
Most molecular biological investigations on LSDV have been done on the Kenya cattle isolate KC-1. 
Restriction enzyme maps based on digestion of the genome with Hind Ill, Pst I, Ava I and Sail have 
been compiled (Gershon and Black, 1987). In contrast, apart from a Hind Ill r.e. map (Gershon and . 
Black, 1988), nothing concerning the molecular biology of the South African vaccine strain, 
Neethling, has been reported. 
Several facts support the idea that these two strains differ from each other. Firstly, there are 
differences in the severity of the disease. Whereas the SA strain caused a high mortality (of up to 
75%) in the 1944 outbreak (Thomas and Mare, 1945), the KC-1 strain caused only 10 deaths in 
the Kenya epidemic in 1957 (MacOwen, 1959). Secondly, KC-1 has the ability to spread from cattle 
to sheep (see section 1.1 0.2), while Capri pox infection has never been reported in South African 
sheep or goats. Finally, although a comparison of the Hind Ill profiles of the two strains 
demonstrated that the genomes were closely related, they differed at two Hind Ill sites (Gershon 
and Black, 1988). 
In the light of the above, it is important to characterise the genome of the S.A. Neethling vaccine 
strain before it can be considered for use as an expression vector for foreign genes. As a departure 
point for molecular investigations, the LSDV genome was cloned. Cloning required purified viral 
DNA of good quality. Since poxviruses are mostly cell-associated, host cell DNA generally co-
purifies with viral DNA. This contaminating host DNA might be ligated into the vector during cloning 
procedures, necessitating lengthy steps to discriminate between cloned viral and cloned host DNA 
fragments. It is therefore essential to reduce the amount of contaminating host cell DNA in viral DNA 
preparations. Various methods for the purification of poxvirus DNA have been described. A 
comparison of three of these methods showed that LSDV DNA, free from host cell DNA 
contamination, could be isolated from virions. 
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Because the size of the LSDV genome (approximately 143 kb), purified DNA cannot be cloned as 
a single unit, but has to be cleaved into smaller fragments, which are more easily cloned. 
Restriction enzyme profiles were compiled to select an enyme that fragments the genome into 
suitable fragments for cloning. A transcription vector was chosen for the cloning experiments as 
it is anticipated that further studies will include mANA investigations. The LSDV clones obtained in 
the cloning experiments were analysed by hybridisation studies to determine the percentage of the 
LSDV genome obtained as clones. 
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2.2 MATERIALS 






N-lauryl sarcosinate (NLS) 
Low-melting point agarose (Seaplaque) 
















5-Bromo-4-chlor-3-indolyi-3-D-galactopyranoside(X-gal) Boehringer Mannheim 
lsopropyi-3-D-galacto-pyranoside (IPTG) Boehringer Mannheim 
2.2.3 Plasmid 
The Bluescribe plasmid (amp') (Stratagene, USA) was used for cloning purposes. 
2.2.4 Radioisotopes 
Deoxycytidine 5' -[ cx-32P]-triphosphate triethylammonium salt with a specific activity of 1200 Ci/mMol) 
and a radioactive concentration of 10 MCi)/ml (370 MBq/ml) was purchased from Amersham 
International (UK). 
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2.2.5 Photographic materials 
Item 
IIford PAN F film 35 mm 
Cronex MRF 31 X-Ray film 
2.2.6 Virus isolate 
Manufacturer 
Ciba Geigy, (Pty) Ltd(Switzerland) 
DuPont (USA) 
The vaccine strain Neethling, an attenuated strain of Lumpy skin disease virus isolated from South 
African cattle, was used throughout this investigation. It was kindly supplied by Dr. B.J. Erasmus 
of the Onderstepoort Veterinary Institute (OVI). 
2.2. 7 Cell cultures 
The Mad in and Darby bovine kidney (MDBK) cell line was used for the propagation of virus and was 
originally obtained from the American Type Tissue Culture Collection (12301 Parklawn Drive, 
Rockville Drive, Rockville, Maryland USA, 20852). The cells were grown on Raux flasks or roller 
bottles (RB) in modified Eagles medium (MacPherson and Stoker,1962), supplemented with 5% 
bovine serum. Virus titrations were performed on primary calf fetal kidney (CFK) cells kindly 
prepared by the Vaccine Development Section, OVI. 




T 4 DNA ligase 
Bacteriophage A. DNA 
Alkaline phosphatase from calf intestine 
Nick translation kit 
Multiprime labelling kit 
Sephadex G75 
HybondN nylon membrane 
Bovine Serum Albumin (BSA) 
Fetal calf serum 
Ficoll 400 










Pharmacia Fine Chemicals 
Amersham International 
Boehringer Mannheim 
Highveld Biological (Pty)Ltd. 
Pharmacia Fine Chemicals 
FMC Broproducts (USA) 
2.3 METHODS 
2.3.1 Virus propagation 
LSDV was propagated in tissue culture according to a procedure developed by Mr. L.M. Pieterse 
of the Vaccine Development Section, OVI. This procedure was aimed at obtaining higher yields of 
virus antigen for vaccine production. Because a relatively small percentage of cells are infected with 
LSDV after initial infection and LSDV seem to have a preference for actively dividing cells (Mr. 
Pieterse, personal communication), this method entailed two passages of infected cells untill most 
cells in the monolayer were infected. 
MDBK cells were grown as monolayers on roller bottles (AS) untill they were 80% confluent. The 
medium was removed and cells rinsed with serum-free Eagles medium. Cells were then infected 
with LSDV stock at 0.1 focus forming units (ffu)/cell, followed by addition of just sufficient medium 
to cover the cells. Viruses. were allowed to adsorb for 60 min, whereupon more medium was added 
and the cells incubated at 37°C. After the first signs of a cythopathic effect (5 days p.i.) the infected 
cells were divided 1 :3 in Eagles medium containing 5% fetal calf serum (FCS) and incubated at 
37°C for a further 5 days. A second passage of the infected cells was then performed. When 
approximately 90% of cells showed a cythopathic effect, the infected cells were harvested. 
2.3.2 Virus titrations 
Titrations were performed on 25 cm2 plastic flasks (Nunc). Serial tenfold dilutions of LSDV viral stock 
to be titrated, were made in Eagles medium. Each dilution of virus was inoculated on a confluent 
monolayer of CFK cells that was rinsed with serum-free medium. Viruses were allowed to adsorb 
for 60 min, more serum-free medium was added and flasks were incubated at 3rC. After 7 days, 
the number of ffu in each dilution was counted. An estimation of the virus concentration calculated 
as ffu/ml could then be made. 
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2.3.3 Purification of LSDV 
LSDV was purified according to a procedure described for vaccinia virus (Mackett eta/., 1985). The 
purification was performed at 4°C. 
LSDV-infected cells were collected from 20 roller bottles by either glass beads or trypsination. The 
cells were concentrated from the medium by low speed centrifugation (1 OOOxg) for 30 min and 
resuspended in 1 OmM Tris-HCI pH 8 at a concentration of 1 x1 08 cells/3 mi. After a 1 0 min 
incubation period on ice, the cells were dounced 20 times and the cellular debris removed by 
centrifugation at 750xg for 7 min. The supernatant was collected, 1/1 00 volume of trypsin (25mg/ml) 
was added and the suspension incubated at 37°C for 30 min. The virus was pelleted by 
centrifugation at 25 OOOxg for 90 min through half a volume cushion of 36% sucrose in 1 OmM Tris-
HCI pH 8. The pellet was.resuspended in a small volume of 1 OmM Tris-HCI pH 8 and sonicated for 
60 sec. MgCI2 was added to a final concentration of 1 OmM and 11.11/ml DNase (1 mg/ml) was added. 
The viral suspension was then incubated at 37°C for 30 min. This was loaded onto 15-40% sucrose 
gradients and centrifuged at 18750xg for 45 min in a Beckman SW41 rotor. The viral band was 
collected, an equal volume of 1 OmM Tris-HCI pH 9 added and the virus concentrated by 
centrifugation at 20 000 rpm in a Beckman SW27 rotor for 15 min. The purified virus was finally 
resuspended in a small volume of 1 OmM Tris-HCI pH 9 and stored at 4°C. 
2.3.4 Purification of LSDV DNA 
2.3.4.1 Purification from a crude preparation of virus 
Viral DNA was purified from a crude preparation of virus after cultivation in cell culture using a 
method described for Orthopox viruses (Esposito eta/., 1981), as follows: 
Monolayer MDBK cells were infected at a multiplicity of infection (m.o.i.) of 0.1 ffu/cell and passaged 
twice as described (section 2.3.1 ). The cells of 10 RB were collected by centrifugation at 1 OOxg for 
30 min and washed in an isotonic buffer (10mM Tris-HCI pH 8, 150mM NaCI, 5mM EDTA). The cell 
pellet was suspended in 36 ml of hypotonic buffer (10mM Tris-HCI pH 8, 10mM KCI, 5mM EDTA) 
and placed at ooc for 10 min. /3ME (0.1 ml) and 10% (v/v) Triton X-1 00 (4ml) was added and the 
incubation continued at ooc for another 1 0 min with occasional gentle mixing. This treatment 
solubilised the plasma membranes and released viral cores, the cell nuclei and cytoplasmic 
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organelles. Cell nuclei were removed by centrifugation at 2000 rpm for 7 min at 4°C and the 
supernatant fluid was centrifuged at 13 000 rpm for 60 min at 4°C in a Beckman SW35 rotor to 
pellet the viral cores. Cores were resuspended in 3.2 ml of ice-cold buffer (1 OmM Tris-HCI pH 8, 
1 mM EDTA, mixed with 60pl of J3ME, 200pl of proteinase K (500 pg) and 0.8 ml of 20% (w/v) N-
lauryl sarcosinate(NLS)). The mixture was incubated at 4°C for 30 min. The NLS lysed the cores 
and released the DNA. S.ucrose, 7.6 ml of a 54% (w/v) solution in water was added and the lysate 
incubated at 55°C for 2 hr to digest proteins. Non-specific binding of residual material to the DNA 
was inhibited by adding 1.6 ml of 5M NaCI to the digested DNA. DNA was purified from the core 
digest by three phenol:chloroform:iso- amylalcohol (50:48:2) extractions. The final aqueous phase 
was removed and extracted twice with an equal volume of chloroform: isoamylalcohol (96:4). DNA 
was precipitated by adding 2.5 volumes of 96% EtOH, collected by centrifugation at 4 000 rpm for 
30 min at 4°C, rinsed in 70% EtOH, air-dried for 5 min and resuspended in 1xTE (1mM EDTA, 10mM 
Tris-HCI PpH 7.5) buffer. DNA was stored at 4°C. 
2.3.4.2 Purification by pulsed field gel electrophoresis 
Pulsed field gel electrophoresis (PFGE) facilities allows the seperation of viral DNA from host cell 
DNA and RNA on agarose gels. Viral DNA may then be recovered from the agarose. The protocol 
followed was described for the extraction of swinepox virus (SPV) from porcine kidney cells 
(Massung and Moyer, 1991 a). 
MDBK cells were infected at a m.o.i. of 0.1 ffu/cell and harvested after two passages of the infected 
cells as described (section 2.3.1 ). The cell concentration/ml medium was then determined by a 
haemacytometer (Neubauer). 
Cells were collected by centrifugation at 1 OOxg for 15 min and resuspended in 0.5 ml phosphate-
buffered saline (10mM sodium phosphate 150mM NaCI pH 7.2) that contained 40mM EDTA. This 
was incubated at 37°C for 5 min. One-half ml of 1.5% low-melt agarose containing 120mM EDTA 
and prewarmed to 42°C was added to the cells and gently mixed until a uniform suspension was 
achieved. The suspension was transferred to an agarose plug mold (supplied with the Rotavor 
system) and the agarose allowed to solidify for 15 min. After solidification, the plugs were removed 
from the mold and incubated for 12-16 hr at sooc in plug lysis buffer (1% NLS, 1 OOpg/ml proteinase 
K, 1 OmM Tris-HCI pH 7.5, 200mM EDTA). The lysis buffer was then removed and replaced with 
sterile 0.5X TBE electrophoresis running buffer (1 X TBE is 89mM Tris base, 89mM Boric acid, 1 mM 
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EDTA} and equilibrated at 4°C for 6 hr with three changes of 0.5X TBE buffer. The viral DNA was 
separated from the cellular RNA and DNA contained within the agarose plug by PFGE using the 
RotavorA Type V (Biometra) system. The following conditions were used: 
Interval 80-20 log (s) 
Angle 115-95 log (0 ) 
Voltage 220 v 
Rotor speed 7 
Temperature 13 oc 
Agarose % low melting point 
Buffer 25 mM TBE 
After analysis of the trial gel, a preparative gel was made with the appropriate amount of cells. The 
isolated band of viral DNA was visualised by staining with EtBr, excised from the gel and 
electroeluted from the agarose by electrophoresis for 2 hr at 1 00 V in dialysis tubing followed by 
a 30 s reverse pulse. The electroeluted viral DNA was ethanol precipitated, resuspended in 1 X TE 
and stored at 4°C. 
2.3.4.3 Extraction of DNA from purified virions 
Purified virus (2.3.3} was diluted with an equal volume of 1% SDS, 20mM B-ME, 20mM EDTA 
solution. Proteinase K was added to a final concentration of 1 OOpg/ml and the mixture incubated 
at 37°C for at least 30 min. DNA was purified by extracting it twice with phenol saturated with 
1 OOmM Tris-HCI buffer pH 8, followed by two chloroform extractions. This was done by adding an 
equal volume of phenol, low speed rocking for 5 min and separating the phenol and aqueous 
phases by centrifugation at 6 000 rpm for 5 min at 20°C. The final aqueous phase was removed 
and extracted with chloroform in the same way. A tenth volume of 3M NaAc and 2.5 volumes of 
96% EtOH were added to the final supernatant, whereupon viral DNA immediately precipitated. The 
DNA was collected by centrifugation at 4 000 rpm for 30 min, rinsed with 70% EtOH, lyophilised, 
resuspended in 1X TE buffer and stored at 4°C. 
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2.3.5 Restriction enzyme digestion of DNA 
Restriction endonucleases (r.e.) are enzymes that cleave double stranded (ds) DNA in a sequence-
dependant manner at specific sites within or adjacent to the sequences. The efficiency of the 
cleavage reaction is , in part, dependent upon the purity of the DNA. Digestions were carried out 
in the recommended high (100mM NaCI), medium (50mM NaCI) or low (10mM NaCI) salt buffer 
supplied with the enzymes and the reaction mixtures contained 4 units of enzyme per J.lg of viral 
DNA Incubation was for 120-180 min at the recommended temperature for the enzyme concerned. 
The digestion products were analysed in agarose gels. 
In cases where r.e. digestions were performed on DNA imbedded in agarose, bovine serum albumin 
to a final concentration of 0.1 mg/ml and spermidine to a final concentration of 0.5mM, was added 
to the reaction volume (200J.il). Also, more enzyme (8-20 units per J.lg of DNA) was used. Incubation 
was performed at the rec;ommended temperatures for at least 4 hr. 
2.3.6 Agarose gel electrophoresis 
Restriction enzyme digested DNA was analysed by electrophoresis in horisontal 0.8% agarose slab 
gels using custom-built electrophoresis equipment. The electrophoresis buffer contained 0.5X TBE 
(1X TBE is 89mM Tris base, 89mM boric acid,1mM EDTA) and gels were made according to the 
method described by Sambrook et at., 1989. DNA samples were mixed with 6X loading buffer 
(0.25% bromo-phenol blue, 40% sucrose in water) prior to loading on the gel. Electrophoresis was 
performed at 20mA for 16 hr, after which the gels were stained with EtBr (0.5J.ig/ml) and visualised 
by UV fluorescence. The gels were destained in buffer tor 60 min and photographed using IIford 
PAN F film and a red and orange filter. 
2.3. 7 Estimation of fragment sizes 
The sizes of DNA fragments were estimated by comparing the migration distance in an agarose gel 
of the unknown fragments with that of molecular size markers of a known size, in the same gel 
during the same electrophoretic run. 
The molecular markers used, were A cl857 Sam? (Boehringer Mannheim) digested with Hind Ill 
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and pAT153 digested with Hinf I. With the sizes of the fragments known, the distance they had 
moved in a gel was plotted (x-axis) against their molecular size in base-pairs (y-axis) on logarithmic 
paper to form a logarithmic curve. The distance the fragments of unknown size had migrated in the 
same gel, was measured and the sizes thus determined from the curve. Using a 0.8 % agarose gel, 
it was impossible to accurately size fragments larger than 20 kb. 
2.3.8 Cloning of LSDV DNA fragments 
2.3.8.1 Purification of fragments by electroelution 
After electrophoretic seperation of r.e. digested DNA (sections 2.3.5 and 2.3.6), fragments of interest 
were selected and excised from the gel. Each gel strip was put into dialisis tubing, to which 3 ml 
of 0.5X TAE buffer (40mM Tris-HCI pH 7.9, 5mM ammonium acetate and 1 mM EDTA) was added 
and the ends of the tubes closed off by a plastic clip. The tubes were placed diagonally in an 
electrophoresis tank, containing sufficient 0.5X TAE buffer to just cover the dialysis tubes. An 
electric current (1 00 V) was applied for 2 hr, followed by a reverse pulse for 30 s, to dislodge the 
DNA adhering to the sides of the dialysis tubing. Each dialysis tube was carefully opened and the 
buffer removed. The tubes were rinsed once with buffer, which was combined with the buffer 
previously removed. DNA was precipitated at -70°C for 2 hr by adding 1/1 0 volume of 3M NaAc and 
2.5 volumes of 96% EtOH and collected by centrifugation at 6 000 rpm for 30 min at 4°C. The DNA 
was washed with 70% EtOH, lyophilised and resuspended in a small volume of 1 X TE buffer. 
2.3.8.2 Size fractionation using sucrose gradients 
In this method, seperation of r.e. digested DNA is accomplished by zonal centrifugation using high-
salt sucrose gradients (Ausubel et a/., 1989). DNA fragments migrate through linear sucrose 
gradients at a rate that is dependant on their size. By collecting relevant fractions of a gradient, 
fragments of a required size range can be selected. 
Linear 1 0-40% sucrose gradients were prepared by hand in SW41 centrifugation tubes. Restriction 
enyzme digested DNA was heated to 65°C for 5 min to dissosiate any DNA aggregates prior to 
layering it on top of the gradients. A maximum of 0.2 mg of viral DNA was used per tube. The 
gradients were centrifuged in a Beckman SW41 rotor at 30 000 rpm for 16 hr at 20°C and then 
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fractionated in Eppendorf tubes by removing 500pl aliquots from the top. The size of the collected 
DNA fractions was determined by subjecting a 30pl sample of each fraction to agarose gel 
electrophoresis using a 0.9% agarose gel. 
Each fraction was then divided into 3 Eppendorf tubes (170pl in each), 330pl of water and 1 ml of 
1 00% EtOH was added and the tubes placed at -20°C overnight. The DNA precipitate was collected 
by centrifugation at 6 000 rpm for 30 min at 4°C. Fractions that contained the DNA fragments of 
interest were pooled and resuspended in 1 X TE buffer. This was used directly for ligations into 
plasmid vectors. 
2.3.8.3 Ligation of DNA fragments 
Vector DNA (pBS) was linearised by digestion with the appropriate r.e. Linearised vector (5pg) was 
incubated in the presence of 20mM Tris-HCI pH 8.0, 1 mM MgCI2, 1 mM ZnCI2 and 1 unit of calf 
intestinal alkaline phosphatase at 37°C for 30 min, to remove its 5'-terminal phosphatase residues, 
in order to reduce the possibility of recircularisation of the vector. The phosphatase was removed 
and vector DNA recovered by a phenol:chloroform:isoamylalcohol (25:24:1) extraction and EtOH 
precipitation, respectively. LSDV DNA fragments were used at a concentration of 0.5pg per ligation 
reaction. Ligations were carried out overnight at 15°C in a final volume of 20pl with 1 unit ofT 4 DNA 
ligase in a buffer containing 50mM Tris-HCI pH 7.6, 1 OmM MgCI2 , 5% (w/v) PEG 8 000, 1 mM ATP 
and 1mM DTT. 
2.3.8.4 Preparation of competent Eschericia coli cells 
The use of CaCI2 to enhance the uptake of foreign DNA by bacterial cells was first demonstrated 
by Mandel and Higa (1 970). It is based on the fact that bacterial cells are made more susceptible 
to the uptake of foreign DNA by treatment of the cells with CaCI2 at ooc. If plasmid DNA that 
expresses a drug-resistance marker is taken up, the marker allows the transformed bacterial cells 
to survive in the presence of an antibiotic. 
A 3 ml overnight culture of E. coli JM105 cells was used to inoculate 400 ml sterile LB medium. The 
culture was grown to log phase (OD590 =0.375) at 37°C with shaking and then placed on ice for 10 
min. The cells were harvested by centrifugation at 4 OOOxg for 5 min at 4°C. The cell pellet was 
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resuspended in 200 mf ice-cold 0.1 M CaCI2 , incubated on ice for 45 min and centrifugated again 
at 4000xg for 5 min at 4°C. The cells were then carefully resuspended in 4 mf ice-cold 0.1 M CaCI2 
containing 15% sterile glycerol and either used after 1 hr at 4°C, or afiquotted into 500pl fractions 
and stored at -70°C. 
2.3.8.5 Transformation procedure 
The ligation reaction mixture (20pl) was added to 150pl of competent E. coli cells and placed on 
ice for 30 min. Uptake of DNA was induced by incubating the cells at 4~C for 2 min followed by. 
a 3 min cooling down on ice. LB medium (0.8 ml, preheated to 37°C} was added and the cells were 
incubated at 37°C for 1 hr to allow for the expression of the antibiotic resistance gene encoded by 
the vector. The cells were then plated onto LB media containing 1.5% agar, ampicillin (1 OOpg/ml), 
X-gaf and IPTG using a spreading technique described by Sambrook eta/., 1989 and incubated 
at arc overnight. X-gaf is a substrate for, and IPTG is an inducer of 
0 
-galactosidase activity, which 
is encoded by the /acZ gene of pBS. When grown on media containing the substrate and inducer, 
E. coli JM 1 05(pBS) is blue in colour. If the lacZ gene is interrupted by the insertion of DNA in to the 
MCS of pBS (Fig 2.6), the bacterial colonies are white. 
2.3.9 Purification of plasmid DNA 
The alkaline lysis method of plasmid DNA extraction described by Birnboim and Daly (1 979) with 
the modifications of lsh-Horowicz and Burke (1 981), was used to isolate plasmid DNA from bacterial 
cells. This method depends upon the fact that a narrow pH range (about 12-12.5) exists within 
which linear DNA, but not covalently closed circular (ccc) DNA, is denatured. Plasmid DNA was 
purified on either a large (from a 400ml overnight culture) or a small ( from a 1Om I overnight culture) 
scale. Volumes for the small-scale purification are indicated in brackets: 
Sterile Luria broth (LB) medium (1% bacto-tryptone, 0.5% bacto-yeast and 1% NaCI adjusted to pH 
7.5) containing the appropriate antibiotic (100pl/ml Amp), was inoculated from a bacterial stock 
culture and incubated at 37°C overnight with shaking. The bacterial cells were harvested by 
centrifugation at 5 OOOxg for 10 min at 4°C and the cell walls were weakened by resuspending in 
10 ml (1 ml) of a solution contain'ing 50mM glucose, 1 OmM EDTA, 25mM Tris-HCI pH 8 and 5 mg/ml 
lysozyme and incubating on ice for 5 min. Complete lysis of the cells was achieved by adding 20 
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ml (2ml} 0.2 M NaOH/1% SDS and incubating on ice for a further 5 min. Protein, high molecular 
mass RNA and chromosomal DNA were precipitated by the addition of 1 0 ml (1 ml) 3M potassium-
acetate pH 4.8. After 1 0 min on ice, the cellular DNA and bacterial debris were pelleted by 
centrifugation at 5 OOOxg for 15 min at 4°C. The plasmid DNA was precipitated by the addition of 
isopropanol (1/2 val) to the supernatant and collected by centrifugation as described above. The 
DNA pellet was resuspended in 1X TE buffer (1mM EDTA, 10mM Tris-HCI pH 7.5} and 
contaminating low molecular mass RNA was removed by precipition with half a volume of 7.5M 
ammonium-acetate. The purified plasmid DNA was finally recovered by precipitation with 2 volumes 
of 96% EtOH. After washing with 70% EtOH, the DNA pellet was lyophilised, resuspended in 1 ml 
(50Jll) 1 X TE buffer and stored at 4°C. 
2.3.1 0 CsCI density gradient centrifugation 
In order to obtain a preparation completely free of contaminating RNA and protein, the plasmid DNA 
was in some instances purified further by centrifugation to equilibrium in CsCI-ethidium bromide 
(EtBr) density gradients. _Because EtBr unwinds DNA when it intercalates, less EtBr can be bound 
by a ccc plasmid than can be bound by a nicked plasmid or chromosomal DNA. Since binding of 
EtBr to DNA lowers its density, the plasmid band appears at higher density (lower down in the tube} 
in equilibrium density gradients. 
The plasmid DNA (1 ml) was mixed with 14 ml of a 1 g/ml solution of CsCI in water and EtBr was 
added to a final concentration of 600Jlg/ml. The gradient was centrifuged to equilibrium at 42 000 
rpm for 16 hr at 20°C in a Beckman Vac50 rotor. Two bands of DNA were visible in UV light. The 
upper band consists of linear bacterial DNA and nicked circular plasmid DNA, while the lower band 
consists of ccc DNA. The lower band was collected with a syringe by inserting a #21 hypodermic 
needle into the side of the centrifuge tube. The fluid was then transferred to a Corex tube. EtBr was 
removed by extracting three times with an equal volume of water-saturated butanol and the DNA 
was recovered by ethanol precipitation. The lyophilised plasmid DNA was resuspended in 0.8 ml 
of 1 X TE buffer and stored at 4°C. 
2.3.11 Characterisation of LSDV clones 
2.3.11.1 Dot-spot hybridisation 
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A Biorad blotting apparatus was used to immobilise DNA onto HybondN nylon membranes. The 
dsDNA was denatured before blotting by boiling at 1 oooe for 1 o min and subsequent snap-cooling 
on ice for 3 min. Blotting was achieved by vacuum action through the blot apparatus. The 
membrane was removed and DNA again denatured by floating the membrane (DNA side up) on 
filter paper saturated with 0.5M NaOH, 1.5M Nael for 5 min, followed by neutralisation on filter 
paper saturated with 1.5M Nael, 0.5M Tris-Hel pH 8, 1 mM EDTA for 5 min. The membrane was 
allowed to air-dry and DNA then fixed by UV-Iight exposure (312 nm) for 3 min on each side. It was 
sealed in a plastic bag and prehybrised in a solution (50% formamide, 5X Denhardts, 20X sse 
0.05M Na-P buffer pH 6.8 and 0.5 mg/ml salmon sperm DNA) at 4~e for at least 4 hr prior to 
hybridisation. If not used immediately, blots were stored in prehybridisation solution at 4°e. 
2.3.11.2 Southern blotting 
Electrophoretic separated r.e. digested DNA was transferred to a membrane to be used in 
hybridisation reactions by a procedure developed by Southern (1975). 
After digestion of LSDV DNA with the appropriate r.e. (section 2.3.5), the fragments were separated 
electrophoretically in 0.8% agarose gels (section 2.3.6). The DNA fragments were denatured by 
gently rocking the gel in a denaturing solution (1.5M Nael, 0.5M NaOH) for 15-30 min. This was 
repeated by changing the denaturing solution twice. The gel was then neutralised by soaking it 
twice in a 1.5M Nael, 0.5M Tris-Hel pH 7.5, 1 mM EDTA solution for 30 min each. The single 
stranded DNA was then ready to be transferred to a HybondN nylon membrane. The transfer was 
effected by a vacuum using 2X sse as blotting buffer. The vacuum was applied for 45 min after 
which the membrane was removed and air-dried. DNA was fixed on the membrane by UV-Iight 
exposure (312 nm) for 3·min on each side. The membranes were further treated as described in 
section 2.3.11. 1 
2.3.12 Labelling of DNA to be used as probes 
2.3.12.1 Nick-translation 
Relevant DNA was labelled with 32P in a nick-translation reaction using the enzyme E. coli DNA 
polymerase I. This enzyme adds nucleotides to the 3'0H-terminus that is created when one strand 
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of a dsDNA molecule is nicked. In addition, the enzyme removes nucleotides from the 5' -side of the 
nick by its 5'- to 3'- exonuclease activity. The elimination of nucleotides from the 5'-side together 
with the sequential addition of nucleotides to the 3' -side, results in movement of the nick (nick 
translation) along the DNA. By replacing the pre-existing nucleotides with highly radioactive 
nucleotides, it is possible to prepare 32P-Iabelled DNA (Sambrook eta/., 1989). 
The commercial kits nick translation mixture comprised 0.05M Tris-HCI pH 7.4, SmM MgCI2, 0.1 mM 
dTTP, 0.1 mM dGTP, 0.1 mM dATP, 1 OJ1Ci 32P dCTP (1 OJ1Ci/J1I with a specific activity of 800 
Ci/mMol), 7.7 units of DNA polymerase! and 2pl of the recombinant plasmid or insert. The reaction 
was carried out for 60 min at 15°C after which the reaction was terminated by placing the mixture 
on ice. The labelled DNA was separated from free nucleotides using a Sephadex G75 column. 
The Sephadex G75 column was packed in a Pasteur pipette and equilibrated with STE-1 buffer 
containing 0.1% SDS. The labelled probe was loaded onto the column and eluted using the same 
buffer. A first fraction of 0.5ml was collected and 0.1 ml samples thereafter. All samples were 
counted for the presence of 32P-cpm. The relevant fractions were pooled and denatured by heating 
at 95°C for 5 min, followed by snap-cooling, just prior to hybridisation. 
2.3.12.2 Random priming 
The principal of this labelling method lies in the use of random sequence hexanucleotides to prime 
DNA synthesis on denatured template DNA at numerous sites along its length (Feinberg and 
Vogelstein, 1983). The Klenow fragment of DNA polymerase I, which lacks the 5'-3' exonuclease 
activity of the intact enzyme, is used in this reaction. It ensures that labelled nucleotides that are 
incorporated by the polymerase are not subsequently removed as monophosphates. The amount 
of newly synthesised DNA often exceeds the amount of input DNA. It is therefore likely that strand 
displacement can occur, so that the same region of a given single strand of input DNA may be 
copied more than once, primed from different hexanucleotides. 
Because a very high specific activity DNA probe is obtainable with relatively small quantities of 
added labelled nucleotides, this method was chosen for labelling of genomic probes and large 
recombinant plasmid probes, using a multiprime DNA labelling kit (Amersham). Very small amounts 
of input DNA (30-100ng), diluted in 10mM Tris-HCI pH 8.0, 1mM EDTA to a volume of 21J1I, was 
denatured by heating at 95°C for 5 min and chilling on ice for 3 min. Unlabeled dATP, dGTP and 
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dTTP (4J1I of each), 5J1I multiprime DNA labelling buffer, 2pl Klenow DNA polymerase, 5J1I [32P]-
deTP and 5J1I of random sequence hexamers was added to the single stranded DNA and the 
reaction was allowed to proceed at room temperature for a minimum for 6 hr, up to 24 hr. The 
labelled DNA was separated from free nucleotides using a Sephadex G75 column as described 
(section 2.3.12.1 ). 
2.3.13 Hybridisation of probes with immobilised DNA 
Hybridisation was carried out after membranes were pre-hybridised in a solution (50% formamide, 
1X Denhardts solution, 4X SSe, 0.02M Na-P buffer pH 6.8, 0.05mg/ml denatured herring sperm 
DNA) for at least 4 hr at 42°e. The solution was then replaced with hybridisation solution with the 
same composition, except that less sperm DNA (0.01 mg/ml) was added. Before the labelled probe 
was added to the hybridasation soluton, it was denatured by heating at gsoe for 5 min and snap-
cooled on ice. Hybridisation was allowed to proceed for at least 16 hr at 42oe after which the 
membrane was removed and washed at the required stringency choosing an appropriate 
temperature and buffer. If high stringency washes were required, 3 washes in 0.1 X sse buffer, 0.1% 
SDS were performed with shaking at 6soe for 15-30 min each. Lower stringency washes were 
performed at 42oe with 3 changes of 1 X sse buffer, 0.1% SDS after 15 min each. 
The membrane was then removed from the washing solution and loaded in an X-ray casette. An 
X-ray film (eronex MRF31) and a [32P]-intensifying screen were placed over the membrane and the 
casette kept at -?ooe for a suitable time. Upon development of the X-ray film, the results could be 
observed on the autoradiogram. 
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2.4 RESULTS 
2.4.1 Growth of Lumpy skin disease virus in tissue culture and virus titrations 
LSDV can be propagated in a variety of cell cultures (Weiss, 1968) of which primary lines are mostly 
used. For this study, the .Madrin Darby bovine kidney (MDBK) cell line (Fig 2.1A) was used. This is 
an established cell line which can be propagated indefinitely. Cytopathic changes in LSDV-infected 
MDBK cells were first noted 4 to 5 days p.i., when foci became visible (Fig. 2.1 B). The infection had 
little effect on the surrounding monolayer, indicating that the virus remained localised and did not 
spread throughout the monolayer. The highest titres on MDBK cells were obtained after two 
passages of virus infected cells (described in 2.3.1) and ranged between 1 x1 05 and 5x1 05 ffu/ml. 
2.4.2 Purification of viral DNA 
Several methods for poxvirus DNA purification have been described in the literature. This section 
describes the results obtained for LSDV DNA purification using three different methods. 
2.4.2.1 Purification from a crude preparation of virus 
Esposito eta/., 1981 developed a method for purification of Orthopox virus strains that grow poorly 
and thus present difficuties in obtaining sufficient amounts of viral DNA. This method was 
·investigated, since LSDV grows relatively slowly and does not reach high titres in cell culture. MDBK 
cells were infected with 0.1 ffu/cell, harvested after two passages and purified (section 2.3.4.1 ). As 
much as Smg LSDV DNN20 RB of infected cells was obtained in this way, but viral DNA was 
excessively contaminated with genomic bovine DNA. This was seen as a smear accompanying the 
viral DNA band when undigested DNA was electrophoretically analysed (Fig. 2.2 lane b) on 0.8% 
agarose gels. The contamination was also later confirmed by hybridisation studies (see section 
2.4.5). A further indication of the poor quality of the DNA, was the restriction enzyme profiles it 
produced. The DNA was digested with restriction enzymes (Fig. 2.2) Bam HI (lane c), Pst I (lane 
d) and Sal I (lane f). In no case, however, were these digestions complete, resulting in poor r.e. 
profiles. No digestion of viral DNA occured with Hind Ill (lane e) or Sma I (lane g), although control 
digestions proved that these enzymes were indeed functional (data on control digestions not 
shown). 
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Figure 2.1 A An uninfected monolayer of Madrin Darby bovine kidney (MDBK) cells. 
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a b c d e g 
Agarose gel (0.8%) electrophoretic analysis of Lumpy skin disease vi ral DNA 
extracted from a crude viral preparation. DNA was digested with the restriction 
enzymes Bam HI (c), Pst I (d) , Hind Ill (e), Sail (f) and Sma I (g) . Undigested DNA 
is shown in lane band Hind Ill digested !.. DNA (lane a) was included as size marker. 
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It should be noted that Esposito's method was not developed specifically for the isolation of ON 
from MDBK cells. Still, the method was applied to viruses cultivated in a variety of cells, including 
primary chick embryo fibroblast and rabbit kidney cells. The formulation of the buffers used for 
lysing the cells and cores might, however, not be applicable to MDBK cells. Nevertheless, the high 
DNA yields that were obtained, justifies further investigation to optimise conditions to be used in 
this specific case. 
2.4.2.2 Pulsed field gel electrophoresis 
In an effort to obtain purified LSDV DNA preparations free of contaminating bovine DNA, the use 
of pulsed field gel electrophoresis as described for purification of SPV DNA (Massung and Moyer, 
1991 a) was investigated. Under pulsed field conditions in an agarose matrix, very large genomic 
DNA is separated from the smaller viral DNA The viral DNA band can then be excised in a gel slice 
and subsequently purified from the agarose. 
MDBK cells were infected with LSDV as described (section 2.3.1), harvested and imbedded in 
agarose plugs. The infected cells were lysed in the plugs and subjected to electrophoresis under 
pulsed field conditions (section 2.3.4.2). In order to standarise the conditions for a preparative gel, 
various amounts of infected cells were subjected to electrophoresis. (Fig. 2.3 A). It was judged that 
1.5x1 07 infected cells (lane f) was the appropriate amount to be used. This resulted in a sharp viral 
DNA band of between 100 kb and 150 kb in length, without overloading (lane e) or underloading 
(lane g) the gel slot. A preparative gel in which 1.5x1 07 cells/ slot was used, is depicted in Fig. 2.3B. 
Using this protocol, viral DNA could be separated completely from contaminating bovine DNA It 
could, however, not be recovered satisfactorily from the agarose gel. Due to the large size 
(approximately 145 kb) of the viral genome, electroelution was the only realistic option to consider. 
Although Massung and Moyer, 1991 a recovered 50J1g of SPV DNN1 07 cells using electroelution 
and their protocol was followed, only minute amounts of LSDV DNA was recovered in this way. 
Even doubling the elution period did not improve the yield. 
The ability to digest the excised viral DNA band directly in the agarose slice (section 2.3.5) was also 
investigated, as this would eliminate the need for elution. Digestions with the r.e. Pst I and Bam HI 
were performed. Electrophoretic analysis in a 0.8% agarose gel (Fig. 2.3C) showed that no 
digestion had occured with either Pst I (lane c) or Bam HI (lane d). 
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a b c d e g h 
Figure 2.3 A Standarisation of conditions for pulse field gel electrophoresis. Different amounts 
of cells, namely 3x1 07 (a & e) , 1.5x1 07 (b & f), 5x1 06 (c & g) were imbedded in 
agarose plugs and analysed on a 1% agarose gel under the following pulsed field 
conditions: Interval 80-20 log (s} , Angle 115-95 log n. Voltage 220 V, Rotor speed 
7, Buffer 25mM TBE, Temperature 13°C. Uninfected MDBK cells (a-c) and LSDV-







Figure 2.3 B Preparative 1% agarose gel run under pulsed field conditions. (a) Lambda ladder 
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Figure 2.3 C Agarose gel (0.8%) electrophoretic analysis of LSDV DNA excised from a pulsed 
field gel and digested directly in the excised slice by Pst I (c) or Bam HI (d). Hind 
Il l digested .l.. DNA (a) and Hint I digested pAT153 (b) were used as size markers. 
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Since adequate amounts of LSDV DNA separated by PFGE could not be eluted from the agarose 
gel, and nor was it possible to restrict the DNA in the agarose, this purification method was not of 
practical use. Consequently, a third method of viral DNA purification, i.e. by extracting DNA from 
purified virions, was investigated. 
2.4.2.3 Purification from virions 
Monolayers of MDBK cells (20 Rb) were infected and harvested as described (2.3.1 ). LSDV virions 
were purified from these cells by lysing the cells, removing the cellular debris, concentrating virus 
from the supernatant and subjecting it to rate sonal centrifugation through sucrose gradients 
(2.3.3). The viral band was collected from the gradients and DNA extacted from the virions by 
phenol-chloroform extractions (2.3.4.3). 
Although this protocol was time consuming and yielded less LSDV DNA (1 mg/20 Rb) than the 
protocol whereby DNA was extracted directly from infected cells (Smg/20 Rb), the quality obtained 
was good. The DNA could be digested with all enzymes used (Fig. 2.4 A and B), resulting in well 
defined r.e. profiles. Undigested DNA showed no smear associated with the viral DNA band (Fig. 
2.4 B lane c). This was taken to indicate the virtual absence of contaminating bovine DNA. This 
DNA was used to compile restriction enzyme profiles, for estimatation of the sizes of r.e. fragments 
yielded (section 2.4.3). 
2.4.3 Restriction enzyme analysis of LSDV DNA. 
The large size of the LSDV genome (approximately 145 kb) necessitated its fragmentation to 
facilitate cloning and easy manipulation. Various restriction enzymes were used to obtain r.e. 
profiles, from which decisions could be made as to which enzyme(s) would be appropriate for 
cloning. 
The aim was to clone as large a portion of the genome as possible, without producing an 
unmanagable number of clones. To accomplish this, an attempt was made to clone large 
fragments, preferably of an appropriate size for either plasmid (0-1 0 kb) or phage lambda vectors 
(8-20 kb), since these systems were available in our laboratory. In the previous section (2.4.2.3), 
various r.e. digestions were performed on purified LSDV DNA (Fig. 2.4 A and B). Digestions of the 
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Agarose gel electrophoretric analysis of LSDV DNA extracted from purified virions 
and digested with various restriction enzymes. 
2.4 A LSDV DNA digested with Pst I (c) and Bam HI (d). Molecular weight markers 
pAT153/Hinf I (b) and .l.. /Hind Ill (a) were included as size markers. 
2.4 B LSDV DNA digested with Hind Ill (d) and Eco Rl (e). Undigested DNA is shown (c), 
wh ile pAT153/Hinf I (b) and .l.. /Hind Ill (a) were included as size markers. 
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genome with Eco AI (Fig 2.4 B lane e) and Hind Ill (Fig 2.4 B lane d) produced many fragments 
ranging in size from between 0.5 kb and 5 kb. On the other hand, Sal I (Fig. 2.2 lane f) yielded 
only a few fragments, most of which were larger than 1 Okb and thus not suitable for these cloning 
systems. LSDV DNA digested with Pst I yielded 9 fragments (Fig. 2.4 A lane c) while Bam HI (Fig. 
2.4 A lane d) produced 11 fragments of between 1 kb and 10 kb. Both enzymes, however, also 
yielded a few larger fragments. Much of the genomic DNA could, however, potentially be obtained 
in only a few plasmid or phage clones. It was thus decided to clone segments generated by Pst 
I and Bam HI. 
The length of each of the fragments generated by LSDV DNA digestion with Pst I and Bam HI was 
estimated from a logarithmic curve (Fig. 2.5), based upon molecular weight size markers. The 
fragments (named in alphabetical order from the largest to the smallest) and their estimated 
lengths, are summarised in Table 2.1. A published result of a LSDV strain isolated in Kenya (KC-1) 
after digestion with Pst I (Gershon and Black, 1987) is also included. No results of LSDV strains 
digested with Bam HI have as yet been published. 
One obvious difference between the profiles of the LSDV vaccine Neethling strain and that of the 
Kenyan KC-1 strain was established, namely that Neethling produced 14 Pst I fragments, while KC-1 
produced only 12. There were, nevertheless, apparent similarities since for most of the restriction 
fragments reported for KC-1, comparable size fragments were obtained with the Neethling DNA 
(Table 2.1, fragments A-H. K, Land N). There were, however, some bands for which corresponding 
fragments could not be identified (Table 2.1, fragments I,J and M of the Neethling strain). 
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Logarithmic curve for estimation of fragment sizes. The distance a fragment 
migrated (x-axis) was measured in mm from the inner edge of the loading well. The 
molecular size (in bp) was plotted on the y-axis on a logarithmic scale. Molecular 




Table 2.1 Fragment sizes of LSDV (Neethling vaccine strain) DNA generated after restriction 
enzyme digestion with Pst I and Bam HI respectively. 
FRAGMENT MOLECULAR SIZE (kb) 
Pstl Pstl* Bam HI 
A 33 39.1 35 .. 
B 23 24.2 21 
c 19 18.9 15 
D 12.7 13.1 12.95 
E 12.2 11.3 11.5 
F 8.9 8.0 10 
G 8.2 7.8 8.6 
H 6.4 7.0 8.2 
I 4.7 5.7 6.0 
J 4.6 3.5 4.7 
K 3.5 3.1 4.2 
.. 
L 3.15 2.2 2.8 
M 2.72 1.83 











Fragments yielded by Pst I digestion of DNA of the Kenia isolate (KC- 1) of LSDV (Gershon and 
Black, 1987) are included (*) for comparison. 
55 
2.4.4 Cloning of the LSDV genome 
Identification of non-essential genes and promoter areas for the development of LSDV as a vector 
depends on the availablility of LSDV clones. Two vector systems, namely a phage lambda system, 
which can accomodate inserts of 8 kb to 20 kb in length and bacterial plasmid vectors, capable 
of accomodating inserts ranging from very small (a few hundred base pairs) to about 1 o kb, were 
considered. The lambda system, pEMBL 12, was investigated but rejected in favour of a plasmid 
vector after a few unsuccesful cloning attempts. These results are therefore not presented. 
Instead, the bacterial plasmid vector pBiuescribe (Fig. 2.6) was chosen. Firstly, it contains the lacZ 
gene which offers a blue-white selection system, allowing easy identification of recombinants. 
Secondly, it also has a multiple cloning site (MCS) which offers a variety of unique restriction 
enzyme sites. Furthermore, pBiuescribe contains the T3 and T7 RNA polymerase initiation regions 
which are potentially useful to allow transcripts to made of the cloned fragment. Lastly, pBS 
contains the sites for the M13 forward and reverse primers, facilitating the direct sequencing of 
inserts. 
2.4.4.1 Selection of a specific size range of LSDV fragments to be cloned 
During a cloning procedure, bacterial plasmids usually tend to incorporate fragments of a relatively 
small size ( <4kb) in preference to those of larger size. To circumvent this tendency which would 
result in only small fragments being cloned, two methods of selecting fragments of a specific size 
range for cloning were investigated, namely electroelution and sucrose gradient fractionation. 
LSDV DNA was digested with Pst I and Bam HI respectively and a sample subjected to agarose 
gel electrophoresis to determine whether the digestion was complete. For electroelution, the 
remainder of the digested DNA was then electrophoresed and fragments of different size ranges 
excised from the gel. The DNA was purified by electroeluting each gel slice separately. Although 
small fragments could be. recovered satisfactorily by this method, the yield of larger fragments was 
poor. Since the aim was to specifically enrich for the large fragments, this method was rejected. 
For the second protocol, r.e. digested LSDV DNA was separated ·on a sucrose gradient at a high 
speed of centrifugation. Fractions of the gradient were collected and a sample of each 
electrophoresed, as this gave an indication as to which fractions were to be used for cloning. 
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In the case of Pst I digested LSDV DNA, fractions 7-14 and 15-25 (Fig. 2. 7 A) were pooled 
respectively. Fractions 1-4 and 5-25 (Fig. 2.7 B) were pooled similarly after a Bam HI digestion. All 
pools were subsequently used for cloning into the plasmid vector pBiuescribe. 
Ace I 
Sal I Sma I Sac I 









The design of the pBiuescribe (pBS) transcription vector. This plasmid confers 
resistance to ampicillin and contains the M13 multiple cloning site (MCS). The Lacz 
gene offers a blue-white selection system of recombinants. The positions of the T3 
and T7 phage promoters as well as of the M13 forward and reverse primer 
sequences are indicated. 
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Figure 2. 7 A Agarose gel electrophoretic analysis of fractions collected after sucrose gradient 
fractionation of Pst I digested LSDV DNA. Gradients were centrifuged at 30 000 rpm 
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Figure 2. 7 B Agarose gel electrophoretic analysis of fractions collected after sucrose gradient 
fractionation of Bam HI digested LSDV DNA The gradient was centrifuged at 30 000 
rpm for 16 hr at 20°C. Fractions 1-4 and 5-24 were pooled respectively for cloning. 
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2.4.4.2 Selection of recombinant clones 
White colonies, indicative of recombinants, were obtained after cloning Pst I and Bam HI LSDV 
fragments into pBS by plating transformed E. coli cultures on Amp/X-gai/IPTG agar plates. Pooled 
fragments that were obtained by sucrose gradients (previous section 2.4.4.1), were used. Cloning 
of the smaller range of fragments produced approximately 40% white colonies, while cloning of the 
larger range produced approximately 15% . Forty Pst I and sixty Bam HI recombinants were picked 
and propagated in an overnight culture. A small scale plasmid extraction was performed on each 
culture and the plasmids digested with either Pst I or Bam HI, depending on the recombinant. 
These were analysed on 1% agarose gels to confirm the presence of inserts. Examples of some 
of these gels are shown (Fig. 2.8 A and B). 
2.4.5 Screening for LSDV-specific clones 
Prior to obtaining LSDV DNA preparations of good quality (purified from virions 2.4.2.3), cloning was 
performed with viral DNA purified directly from cell cultures (section 2.4.2.1 ). Since this DNA was 
contaminated with bovine genomic DNA, it was anticipated that a percentage of these recombinants 
would contain bovine and. not LSDV inserts. Screening for LSDV-specific clones was performed by 
subtractive dot-spot hybridisation (section 2.3.11.1 ). Extracted plasmid DNA from each recombinant 
was immobilised onto nylon membrane, denatured and hybridised to a bovine genomic DNA probe, 
extracted directly from MDBK cells (section 2.3.4.1) and labelled by random priming (section 
2.3.13.2). As controls, genomic LSDV DNA (Fig. 2.9 A, lane a8) purified by Esposito's method, 
genomic bovine DNA (Fig. 2.9 A, lane b8) and pBiuescribe vector DNA (Fig. 2.9 A, lane c8) were 
also spotted. High stringency washes (> 90% homology) of the membrane ensured that positive 
hybridisation signals (light spots, Fig. 2.9 A) were those representing cloned bovine DNA. Such 
recombinants were discarded, whereas those which did not hybridise to the bovine probe, were 
assumed to be LSDV-specific. This result also confirmed that the LSDV DNA purified directly from 
cell culture was indeed contaminated. as it reacted positively to the bovine probe (Fig. 2.9 A, lane 
a8). As was expected, the strongest hybridisation signal was obtained from the positive control , i.e. 
the immobilised bovine genomic DNA (Fig. 2.9 A, lane b8) . 
To confirm the identity of those recombinants which did not react to the bovine probe, an identical 
blot was hybridised to a labelled genomic LSDV DNA probe (Fig. 2.9 B) . This, however, was 
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Figure 2.8 A Agarose gel electrophoretic analysis of recombinants obtained after cloning Pst I 
digested LSDV fragments into pBS. White colonies were selected, plasmids 
extracted and DNA digested with Pst I (d-u), to determine which contained an insert. 
Linearised pBS (c) was included as a positive control, while Hind Ill-digested A. DNA 
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Figure 2.8 B Agarose gel electrophoretic analysis of recombinants obtained after clon1ng 
Bam HI digested LSDV fragments into pBS. White colonies were selected and 
extracted plasmids digested with Bam HI to determine which contained an insert 



















Figure 2.9 A and B 
b c d e g h k 
Dot-spot hybridisation of recombinant pBS clones (rows 1-7) to a (A) bovine 
genomic and (B) LSDV genomic probe. Identical membranes were used. 
Purified LSDV (lane a8), bovine (lane b8) and pBS (lane c8) DNA were 
spotted onto the membranes as controls. 
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bovine (Fig. 2.9 B lane b8) DNA hybridised to the probe. The immobilised bovine DNA cross-
hybridised to the LSDV probe, since the viral DNA used to prepare the probe was slightly 
contaminated with bovine DNA. 
The absence of any hybridisation signals from the recombinants, may be explained by taking copy 
numbers into account. Since the entire genome of LSDV was used as a probe, only a limited 
number of any specific segment would be present and labelled. As such, even if hybridisation did 
occur, it could not result in a positive signal. This problem was solved by reversing the approach 
and using DNA from a specific recombinant as a probe, thereby labelling only the insert of interest. 
Each recombinant was radioactively labelled by nick translation (section 2.3.13.1) and hybridised 
to immobilised LSDV- and bovine genomic DNA respectively (Fig. 2.11 B). 
2.4.6 Southern blotting of LSDV recombinants 
To identify the cloned LSDV fragments (cloned as either Pst I or Bam HI fragments), Southern 
blotting was performed (section 2.3.11.2). Preparative agarose gels of either Pst I (Fig. 2.1 o A) or 
Bam HI (Fig. 2.1 0 B) digested LSDV DNA were made and the DNA blotted onto a nylon membrane. 
A membrane was cut into strips that were then hybridised to each prospective LSDV recombinant, 
identified in the previous section (2.4.5). 
The specific Pst I or Bam HI fragment a recombinant contained, in the case of those 
accommodating small LSDV fragments, was easily identified from autoradiographs in this way (Fig. 
2.11 A and 2.12. This included those containing the Bam HI fragments (Fig 2.12) M (pKV28), N 
(pKV13, pKV17, pKV36, pKV39, pKV44), 0 (pKV4) and P (pKV20, pKV33, pKV46) and also 
recombinants containing the Pst I fragments (Fig 2.11 A) K (pKV9) and N (pKV6). Results 
concerning these recombinants are summarised in table 2.2 (page 72) . 
In the case of recombinants containing large LSDV fragments, the specific Pst I or Bam HI fragment 
could, however, not be identified by Southern blotting, since the large fragments were not 
sufficiently separated on preparative agarose gels and had a poor resolution (Fig. 2.10 A and B) . 
As such, those containing identical sized fragments could also not readily be identified. The 
identification of the specific large fragment a recombinant contained, was instead performed by 
double digestion of the DNA. 
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Figure 2.1 0 A 
A preparative agarose gel 
of Pst I digested LSDV DNA 
Figure 2.1 0 B 
A preparative agarose gel 
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Figure 2.11 A 
Autoradiogram of Southern blotting 
performed on Pst I digested LSDV. 
Pst I recombinants as indicated 
above the autoradiograph, were 
used as probes. A genomic LSDV 
probe was included as a contml. 
Figure 2.11 B 
Dot spot hybridisation of the pKV6 
(b), pKV9 (c), pKV1 0 (d) , pKV1 8(e), 
pKV21 (f) and pKV23 (g) probes to 
genomic LSDV (I) and bovine (II) 
DNA. A genomic LSDV probe (a) 

































































Autoradiograph of Southern blotting performed on Bam HI digested LSDV. DNA of 
Bam HI recombinants as indicated above the autoradiograph , were used as 
probes. A genomic LSDV probe was included as control. Dot spot hybridisat1on 
of these clones to genomic LSDV and bovine DNA (as in Fig. 2.10 B) was also 
performed to confirm that they were indeed LSDV-specific, but results are not 
presented. 
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2.4. 7 Double digestion 
In cases where the identity of the large sized cloned LSDV DNA fragments could not be identified 
by Southern blotting (Fig. 2.11 A pKV1 0, pKV18, pKV21, pKV23 and Fig. 2.12 pKV43, pKV52, 
pKV53, pKV55 and pKV56) , double digestion was performed on DNA of those recombinants. The 
DNA was digested simultaneously with the r.e. used to clone the fragment (which yielded the intact 
vector pBS and the insert) and with another r.e. present in the multiple cloning site of the vector 
(which cleaved the insert into smaller pieces, but not the vector). In this way the length of the insert 
could be determined accurately, allowing identification of the specific fragment. Furthermore, 
recombinants containing the same fragment, had the same r.e. profile after this double digestion 
procedure and could thus be identified. 
Pst I recombinants pKV1 0, pKV18, pKV21 and pKV23 were digested with either Pst I + Eco Rl or 
Pst I + Cia I. Digestions with Pst I, which yielded the intact insert, were also performed. 
Electrophoretic analysis (Fig. 2.13 A) indicated that pKV21 and pKV23 (lanes i and j; m and n) 
contained the same insert, since they had the same r.e. profiles after the double digestions, i.e. 
neither had Eco Rl or Cia I sites in their inserts. For furher conformation these two recombinants 
were also digested with Pst I + Hind Ill (results not shown) and again, both had no internal Hind 
Ill site. It would therefore seem that pKV21 and pKV23 contain the same insert. It might, however, 
be a coincidence that neither has internal recognition sites for these restriction enzymes and that 
they actually do contain different inserts. Definitive proof can be obtained by cross-hybridising the 
pKV21 and pKV23. pKV1 0 and pKV18 showed different r.e. profiles after double digestions with the 
same combination of restriction enzymes (Fig. 2.13 A lanes g and h ; k and I) and therefore contain 
different inserts. 
Bam HI recombinants pKV43, pKV52, pKV53, pKV55 and pKV56 were analysed by digesting them 
with Bam HI (which yields the intact insert) , Bam HI + Hind Ill and Bam HI + Eco Rl (Fig. 2.13 B) . 
The results of the Bam HI digestion indicated that more than one insert was apparently cloned into 
pKV52 and pKV53 (lanes b and c), which might be attributed to either incompletely digested LSDV 
fragments or incorporation of more than one fragment. 
Double r.e. digestions of pKV55 and pKV56 (Fig. 2.13 B lanes I and m ; q and r) resulted in identical 
r.e. profiles, verifying that the same LSDV fragment had been cloned in both recombinants. 
Recombinants pKV43 and pKV53 (Fig. 2.13 B lanes i and k ; n and p) also had similar, but not 
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Figure 2.13 A Electrophoretic analysis of LSDV/Pst I recombinants after double digestions. 
(a) pKV1 0/Pst I (b) pKV18/Pst I (c)pKV21/Pst I (d)pKV23/Pst I 
(e) A/Hind Ill (size marker) 
(g) pKV1 0/Pst I + Eco Rl 
U) pKV23/Pst I + Eco Rl 
(m) pKV21 /Pst I + Cia I 
(0 .l.. /Hind Ill+ Eco Rl (size marker) 
(h) pKV18/Pst I + Eco "AI (i) pKV21 /Pst I + Eco Rl 
(k) pKV1 0/Pst I + Cia I (I) pKV18/Pst I + Cia I 
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Figure 2.13 B Electrophoretic analysis of LSDV/Bam HI recombinants after double digestions. 
(a) pKV43/Bam HI (b) pKV52/Bam HI (c) pKV53/Bam HI (d) pKV55/Bam HI 
(e) pKV56/Bam HI (f) pAT153/Hinf I (size marker) (g) A/Hind Ill (size marker) 
(h) A/Hind 111/Eco Rl (size marker) (i) pKV43/Bam HI + Hind Ill 
U) pKV52/Bam HI + Hind Ill (k) pKV53/Bam HI + Hind Ill (I) pKV55/Bam HI + Hind Ill 
(m) pKV56/Bam HI + Hind Ill (n) pKV43/Bam HI + Eco Rl (o) pKV52/Bam HI + Eco Rl 
(p) pKV53/Bam HI + Eco Rl (q) pKV55/Bam HI + Eco Rl (r) pKV56/Bam HI + Eco Rl 
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c, k and p). In the Bam HI + Hind Ill digestion of pKV53 (lane k) two 1.7 kb fragments were present, 
evident from the double intensity of the band. On the Southern blot, however, both pKV43 and 
pKV53 hybridised at the same position (Fig. 2.12), i.e. to a fragment of approximately 8 kb in length. 
Surprisingly, pKV53 did not hybridise to any other LSDV fragment, 
which would be expected, considering the fact that it apparently contained 3 Bam HI LSDV 
fragments. The extra fragments were not of bovine origin, since pKV53 did not hybridise to genomic 
bovine DNA in dot-spot hybridisation (result not shown). Apart from speculating that these extra 
fragments may be due to star activity of Bam HI, no concrete explanation can be given. They were 
not further investigated and omitted from calculations. 
The total length of both inserts of pKV52 as calculated from the double digestions (Fig. 2.13 B lanes 
j and o) was found to be 14.3 kb. Since the smaller insert was 2.8 kb (from Fig. 2.13 B lane b), the 
larger fragment would be 11.5 kb in length, i.e. the E fragment of Bam HI digested LSDV DNA. On 
the Southern blot (Fig. 2.12) pKV52 hybridised only to a fragment of approximately 14 kb. This 
could be explained if the LSDV DNA used for the preparative gel was not digested to completion 
and the pKV52 probe all hybridised to the incompletely digested fragment. It therefore seems as 
if pKV52 contains the E and a fragment of 2.8 kb, corresponding to the L fargments of Bam HI 
digested LSDV DNA. 
A summary of the results of the double digestions, where sizes of all inserts were calculated from 
logarithmic curves (section 2.3.7) are given in table 2.2 *). In this table the combined results of the 
Southern blotting and double digestions as to which Pst I and Bam HI fragments were finally 
cloned, are presented. 
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Table 2.2 A summary of the specific LSDV Pst I (A) and Bam HI (B) fragments that had been 
cloned based on analysis of recombinants by Southern blotting and double 
digestions (*) . 
Recombinant Pst I fragment Size in kb 
pKV6 N 2.3 
pKV9 K 4 
* pKV10 F 8.9 
* pKV18 G 8.2 
* pKV21 , pKV23 H 6.4 
Total length cloned as Pst I fragments : 29.8 
Recombinant Bam HI fragment Size In kb 
pKV20, pKV33, pKV46 p 1.12 
pKV4 0 1.33 
pKV13, pKV17, pKV36, N 1.62 
pKV39, pKV44 
pKV28 M 1.83 
* pKV43 H 8.3 
* pKV53 H +unknown 8.3 
* pKV52 E + L 11.5 + 2.8 
* pKV55, pKV56 D 12.95 
Total length cloned as Bam HI fragments : 41.45 
Total length of the LSDV genome cloned (Pst I + Bam HI fragments ) : 
29.8 kb + 41.45 kb 71 .25 kb 
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Figure 2.14 










Autoradiograph of Southern blotting performed by hybridising the different Pst 1 
recombinants to Bam HI digested LSDV DNA. pKV6 (a), pKV9 (b), pKV1 0 (c), pKV18 
(d) , pKV21 (e) and pKV23 (D were used as probes. A genomic LSDV probe 
hybridised to Bam HI digested genomic LSDV DNA was included as a control (g) . 
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To calculate the LSOV genome portion which was finally cloned, the possibility that the Pst I 
recombinants contained the same or overlapping regions as the Bam HI recombinants, were 
considered. For verification, the Pst I recombinants were radioactively labelled and hybridised to 
electrophoretically separated Bam HI digested LSDV DNA, blotted onto a nylon membrane (section 
2.3.11.2). The reasoning !;>eing that, because it was now known which LSDV/Bam HI fragments had 
been cloned {Table 2.3), LSDV/Pst I recombinants that hybridised to those specific Bam HI 
fragments shared mutual sequences with it, signifying common inserts .. 
Results (Fig. 2.14) demonstrated that all of the Pst I recombinants hybridised to very large Bam HI 
fragments, i.e. those larger than was cloned. It was therefore concluded that none of the 
recombinants shared common inserts. The total length of the LSDV genome cloned was 
subsequently calculated by adding the cloned Pst I {29.8 kb, table 2.3) and Bam HI {41.45 kb, table 
2.3) fragments, amounting to 71.25 kb. This represents nearly 50 % of the 143 kb LSDV genome. 
74 
2.5 DISCUSSION 
In this study, approximately 50% of the LSDV genome (Neethling vaccine strain) was cloned into 
the plasmid vector, pBiuescribe. To accomplish this, purified DNA of good quality had to be 
acquired. Three methods of purification were investigated: DNA was purified from a crude viral 
preparation (Esposito eta/., 1981) and although relatively large quantities (5mg LSDV DNN20 RB) 
could be obtained in this way, the LSDV DNA was excessively contaminated with bovine DNA. 
Since such contamination complicates cloning procedures, this was not considered to be an 
appropriate method. Secondly, LSDV DNA was separated from bovine DNA by pulsed field agarose 
gel electrophoresis and extracted from the gel by electroelution. The problem of contaminating DNA 
was overcome, but inadequate amounts of LSDV DNA for cloning were recovered. The best quality 
of reasonable amounts (1 mg/20 RB) of LSDV DNA was finally obtained by extracting it from purified 
virions. Although DNA yields were lower than was obtained by direct extraction, almost no 
contaminating bovine DNA was present. 
Using the DNA isolated from purified virus, various restriction enzyme profiles were compiled. Pst 
I and Bam HI digestions yielded several fragments of 3 kb to 1 0 kb in size and were thus used for 
cloning. The LSDV genome length was estimated from these restriction enzyme profiles and found 
to be approximately 145 kb, a size similar to that of the Kenya isolate, KC1. (Gershon and Black, 
1987). A limitation was that lengths of the large fragments (> 20 kb) could not be determined 
accurately due to the poor resolution in the agarose gel system used. This estimate is therefore 
likely to be subject to an error rate, which might be as high as 15% . The use of pulsed field gel 
electrophoresis could conceivably improve the resolution of the large fragments and allow more 
accurate sizing of the genome. Since accurate sizing was not one of the aims of this investigation, 
PFGE was not performed for this purpose. 
DNA isolated from the LSDV Neethling and KC-1 (Gershon and Black, 1987) isolates yielded 
different Pst1 restriction enzyme digestion profiles. (see table 2.1, page 54). The Neethling strain 
produced 14 Pst I fragments, in contrast to the 12 of KC-1. There were, nevertheless, apparent 
similarities since for most of the restriction fragments reported for KC-1, comparable size fragments 
were obtained with the Neethling DNA (table 2.1, fragments A-H, K, Land N). There were, however, 
some bands for which corresponding fragments were not identified. It should be noted that a 
limitation of such comparisons is that it is impossible to determine the origins of such 
discrepancies. Despite this, the differences in restriction enzyme profiles are an indication that the 
Neethling and KC-1 isolates represent two distinct strains. 
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The major aim of this section of the work was the molecular cloning of the genome. Since restriction 
enzyme digestions yielded a wide range of fragment sizes, it was necessary to enrich for the larger 
fragments by means of sucrose density gradient centrifugation to obviate producing an 
unmanageable number of clones and duplication of small fragments. DNA fragments of 8.2 kb (G 
fragment of Pst 1/LSDV), .8.9 kb (F fragment of Pst 1/LSDV), 8.3 kb (H fragment of Bam HI/ LSDV), 
11.5 kb (E fragment of Bam HI/LSDV) and 12.95 kb (D fragment of Bam HI/LSDV) were successfully 
cloned into the Bluescribe plasmid. Together with a number of smaller segments, this represents 
approximately 50% of the LSDV genome. These relatively large inserts are not likely to be deleted 
from this plasmid according to the product information sheet of the supplier. 
The availabilty of these clones now opens the door for further molecular characterisation of the 
LSDV (Neethling) genome. One of the projected aims is to identify strong promoter sequences 
present in the cloned fragments. A strong promoter is required to drive the expression of foreign 
genes if LSDV is to be used as an recombinant vaccine vector. The amount of transcribed mANA 
is an indication of the strength of a promoter and has been used for promoter identification (Kumar 
and Boyle, 1990) by means of Northern blot hybridisation. Messenger RNA will be extracted from 
LSDV infected cells and hybridised to each recombinant obtained in this study. This will allow 
identification of specific recombinants which contain genes that are strongly expressed. Such genes 
may probably be under the control of strong promoters. The DNA from such recombinants may 
then be examined further-to accurately locate the structural gene and its accompanying promoter. 
This should facilitate further detailed characterisation of the promoter. 
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CHAPTER THREE 
TAILORING AND SEQUENCING OF BTV4 VP5 
3.1 INTRODUCTION 
Even though the development of LSDV as a live recombinant vector is still in its initial stages, a trial 
gene to be cloned and expressed in this system was prepared and sequenced. The gene decided 
upon was a gene of South African bluetongue virus serotype 4, coding for viral protein 5 (SA-BTV4 
VP5), a component of the outer capsid of the virus. This was partly done in order to gain 
experience in the methodology involved, but would also serve other purposes as this gene is to be 
·, 
cloned into the vaccinia virus system by other researchers in our laboratory. 
At least 24 BTV serotypes have been identified (Gorman eta/., 1983; Knudson and Shope, 1985) 
and VP2 has been shown to be the principal serotype-determining antigen (Huismans and 
Erasmus, 1981; Kahlon eta/., 1983, Mertens eta/., 1989). It elicits neutral ising antibodies in sheep, 
capable of protecting against virulent challenge (Huismans eta/., 1987). Wade-Evans eta/. (1988) 
have shown that VP5 may play a role in the determination of serotype and there is evidence that 
immunisation with soluble VP2 and VP5 can induce higher titres of neutralising antibodies than 
immunisation with VP2 alone (Huismans eta/., 1987; Roy eta/., 1990). The actual function of VP5 
is however not yet known. Expression in a recombinant expression system, such as W or LSDV 
might facilitate knowledge in this regard. 
Huismans and Cloete (1987) have cloned the eDNA form of BTV4 VP5 into the bacterial plasmid 
vector pBR322 and designated the recombinant p73, using a GC-homopolymeric tailing strategy. 
This strategy involved the addition of homopolymer tails in two different stages. In the first stage 
poly(A) tails were synthesised at the 3'-termini of the dsRNA segment using E. coli polyA 
polymerase, to provide oligo-dT priming sites for reverse transcription. Secondly, oligo-dC tails were 
added to the 3' -termini of the cDNAs. The eDNA was then annealed to Pst !-digested oligo-dG tailed 
pBR322 vector, to produce the recombinant. It is known, however that these homopolymeric 
sequences which are present at the termini of the gene, inhibit expression of the cloned gene (eg. 
Steuber et a/. 1984; Galili eta/. 1986). It is therefore necessary to remove these sequences prior 
to cloning into an expression system. This chapter describes the strategy followed to tailor the gene 
by means of the polymerase chain reaction (PCR) and the sequencing of the resulting BTV4 VP5 




The following primers were synthesised and supplied by the Biochemistry department, UCT under 








5'- ATCC GGATCC 
Bam HI 
GTAAGTGTAAGCTTC -3' 
3' -terminal of ( -) strand 
OP-12 is a 25-mer consisting of 15 deoxynucleotides complementary to the 
3'-terminal end of the B1V4 VP5 non-coding strand and preceded by a 5'-
non-complementary decanucleotide sequence which specifies a Bam HI 
site (underlined). The 4-nucleotide 5'-extension sequence was included to 
stabilise the r.e. site. 
5'- ATCC GGATCCG 
Bam HI 
TTAAAAGTATTCTC -3' 
3'-terminal of(+) strand 
OP-11 is a 25-mer consisting of 15 deoxynucleotides complementary to the 
3'-terminal end of the B1V4 VP5 coding strand and preceded by a 5'-non-
complementary decanucleotide sequence which specifies a Bam HI site 
(underlined). The 4-nucleotide 5'-extension sequence was included to 
stabilise the r.e. site. 
Recombinant plasmid P~.3 (amp', tef1 which contains the VP5-gene of bluetongue virus serotype 
4 (Huismans and Cloete, 1987) was kindly provided by Prof. H. Huismans, Department of Genetics, 
University of Pretoria, Pretoria. Plasmid pUC13 was purchased from Clontech Laboratories, Inc. 
(USA). 
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3.2.3 Radio-isotopes 
Deoxyadenosine 5'-a-[35S]-thiotriphosphate triethylammonium salt with a specific activity of 1000 
Ci/mMol and a radioactive concentration of 1 0 mCi/ml (370 MBq/ml) was purchased from 
Amersham International (UK). 
3.2.4 Reagents used for sequencing 
Item Manufacturer 
TaqTrack™ sequencing kit 
RNaseA 
PEG 6000 
M13 forward and reverse primers 
3.2.5 Photographic material 
Item 
IIford PAN F film 35mm 
Cronex MRF 31 X-Ray film 







Ciba Geigy, (Pty)Ltd.(Switzerland) 
Dupont (USA) 
Manufacturer 
Bio 1 01 Incorporated (USA) 
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3.3 METHODS 
3.3.1 Polymerase Chain Reaction 
The Polymerase Chain Reaction (PCR) procedure was originally described (Saiki et a/., 1985) as a 
means of amplifying a specific region of which the flanking sequences are known. It also provides 
a method whereby the ends of cloned genes may be tailored (Dennis, 1990). The reaction consists 
of successive cycles of denaturation and extension of sequence-specific primers by a heat resistant 
DNA polymerase of Thermus aquaticus (Taq DNA Polymerase). 
The DNA template (1 00-500ng of dsDNA) was diluted in the presence of an excess (2.5J.1g each) 
of the oligonucleotide primers OP-11 and OP-12 to a volume of 38J.1I in water. To this was added 
1 OJ.1I 1 mg/ml BSA; 8J.1I each of 1 OmM dATP, dCTP, dGTP and dTIP and 20J.1I SX Taq polymerase 
buffer (0.335M Tris-HCI pH 8.8, 33.5mM MgCI2, 83mM (NHJ2S04, 50mM ,13-ME) which brought the 
reaction mix to a final volume of 1 OOJ.11. To avoid evaporation, liquid paraffin (1 OOJ.1I) was placed 
carefully over the reaction mix and the DNA was denatured at 94°C for 5 min. The primers were 
then allowed to anneal by incubating the mix at 37°C for 2 min, followed by the addition of 1J.1I (2.5 
units) of Taq polymerase through the paraffin layer. The extension reaction was carried out by 
incubating at 72°C for 6 min. Twenty cycles of PCR (denaturation 1 min at 94°C, annealing 2 min 
at 37°C, extension 6 min 72°C) were performed manually. A sample of the reaction mix was 
analysed in a 1% agarose gel. 
3.3.2 Purification of DNAfrom agarose by the Geneclean™ method. 
DNA was purified according to the manufacturer's instructions as outlined below. After 
electrophoretic separation of the DNA; the VP5-gene band was cut out of an EtBr-stained gel and 
mixed with the saturated Nal solution. The gel was dissolved at 55°C for 5 min followed by the 
addition of 1J.1I glassmilk™ per 0.5J.1g DNA Glassmilk™ is a silica matrix in water which binds rapidly 
to DNA; but not RNA at ambient temperature. After 5 min, the silica matrix with bound DNA was 
pelleted by centrifugation in an IEC Centra-M benchtop microcentrifuge and washed three times 
with ice-cold NEW™ (NaCI, Ethanol, Water) ~wash. The DNA was finally eluted from the silica by 
resuspending in 15J.1I water and incubating at 55°C for 2 min. The elution step was repeated twice 
more to yield a final volume of 45J.1I purified DNA 1 OJ.1I of this DNA was used for the ligation step. 
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3.3.3 Ligation procedure 
Vector DNA was linearised by digestion with the BamHI restriction enzyme. The vector was 
dephosphorilated by adding alkaline phosphatase enzyme and incubating at 37°C for 30 min. The 
enzyme was then removed by extraction with an equal volume of phenol:chloroform:isoamylalcohol 
(25:24: 1) and the vector DNA recovered by ethanol precipitation. Ligations were carried out 
overnight in a final volume of 20pl with 1 unit of T4 DNA ligase at 15°C in a buffer containing 50mM 
Tris-HCI pH 7.6, 1 OmM MgCI2, 5% (w/v) PEG 8000, 1 mM ATP and 1 mM OTT. 
3.3.4 Transformation procedure 
Transformation was performed as described in Chapter two, section 2.3.8.5. 
3.3.5 Sequencing 
Sequencing was performed on plasmid DNA using the commercially available TaqTrack™ sxstem, 
which is an enzymatic dideoxynucleotide method (Sanger et a/., 1987) with a labelling method 
developed by Tabor and Richardson (1987). In this method, the sequencing reaction is separated 
into a labelling step and an extension/termination step. In the first step, the primer is extended a 
short distance using limiting concentrations of the dNTPs and a single radiolabeled dNTP. In the 
second step, the extended primers are further extended in the precence of both dd~ and dNTPs. 
Sequencing is performed with the Taq DNA polymerase enzyme, which is a thermostable enzyme 
purified from Thermus aquaticus and replicates DNA at 74°C. 
3.3.5.1 RNase-PEG precipitation of plasmid DNA 
All reactions were carried out in 1.5 ml Eppendorf tubes. CsCI-purified plasmid DNA (30pg 
in 150pl water) was incubated with 3pl 1 Omg/ml RNAse A at 37°C for 30 min. DNA was precipitated 
with the addition of 90pl PEG solution (20% PEG 6000, 2.5M NaCI) followed by incubation on ice 
for 15 min. The precipitate was collected by' centrifugation for 15 min in a Sigma MK2 Eppendorf 
benchtop centrifuge, rinsed with 70% EtOH, lyophilised and resuspended in deionised distilled 
water. 
3.3.5.2 Denaturation of template DNA 
For a single sequencing reaction, 4pg DNA-was denatured in 0.2M NaOH, 2mM EDTAfor 
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5 min at room temperature. The mixture was neutralised by the addition of 0.4 volumes of 5M 
ammonium-acetate and the DNA-precipitated with 3 volumes of 96% EtOH. After 10 min at -70°C, 
the DNA was collected by centrifugation for 1 o min in a Sigma MK2 benchtop centrifuge, rinsed 
with 70% EtOH and lyophilised. 
3.3.5.3 Annealing template and primer 
The denatured DNA was redissolved in 16J..1I of deionised distilled water and 5J..II Taq DNA 
polymerase 5X buffer (250mM Tris-HCI pH 9, 50mM MgCI:J, 2tJI of the extension/labelling mix 
(7.5J..1M each of dGTP, dTTP and dCTP) and 2tJI (2ng) of the appropriate sequencing primer added. 
The mixture was incubated at 37°C for 1 0 min. 
3.3.5.4 Extension/labelling reaction 
To the 25J..1I of annealed primer-template mixture, the following were added: 2tJI of a-35S-
dATP (1 OOOCi/mMol) and 1.6J..II of sequencing grade Taq DNApolymerasel (2.5J..1g/J..II). The reaction 
was incubated at 37°C for 5 min. This reaction is carried out at 37°C rather than 70°C to slow down 
the incorporation rate of the enzyme and thereby limit the number of bases incorporated in this 
step. This allows the sequence to be read close to the primer. 
3.3.5.5 Termination reaction 
Four tubes were labelled A; C, G, and T and 1J..1I of the appropriate d/ddNTP mix, with the 
following composition, was placed in its corresponding tube: 
Component G A T c 
nucleotide mix nucleotide mix nucleotide mix nucleotide mix 
ddGTP 50J..1M - - -
ddATP - 350J..1M - -
ddTTP - - 600J..1M -
ddCTP - - - 160J..1M 
.. 
dGTP 25J..1M 250J..1M 250J..1M 250J..1M 
dATP 250J..1M 25J..1M 250J..1M 250J..1M 
dTTP 250J..1M · 250J..1M 25J..1M 250J..IM 
dCTP 250J..1M 250J..1M 250J..1M 25J..1M 
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When the extension/labelling reaction was complete, 6f.1l of this mix was aliquotted to each of the 
four tubes, mixed and incubated at 70°C for 5 min. The reaction were stopped by the addition of 
4f.1l stop solution (95% formamide, 10mM NaOH and 0.05% each of Bromophenol Blue and Xylene 
Cyanol FF). The tubes were heated to 90°C for 5 min immediately before loading 3 f.ll samples onto 
a gel. 
3.3.5.6 Polyacrylamide gel electrophoresis 
The sequencing reactions were analysed by polyacrylamide gel electrophoresis in gels 
containing 6% acrylamide (from 38% acrylamide, 2% bisacrylamide stock solution), 8M urea and 
1X TBE (90mM Tris-HCI pH 8.3, 90mM boric acid, 2.5mM EDTA). Electrophoresis was carried out 
in 0.5X TBE on a BRL model S2 sequencing apparatus using an LKB 2197 power supply. Gels were 
run at 2000 V, equivalent to 70 Watts and 40 rnA; After electrophoresis, the gel was dried and 




3.4.1 Tailoring of the cloned BTV4 VP5-gene segment using PCR 
The tailoring of cloned eDNA fragments by means of the polymerase chain reaction (PCR) was 
originally described by Dennis (1990). The method involves the use. of oligonucleotide primers 
complementary to the eDNA sequences immediately adjacent to the homopolymer sequences, to 
produce amplification products. An outline of the procedure is given in Fig. 3.1. Denatured dsDNA 
recombinant p73 was used. as template for the PCR procedure to generate large amounts of the 
' 
VP5 DNA it contained . Because only a small amount of starting material was used, the majority of 
the products contained the termini which were specified by the primers. Primers were constructed 
in such a way that they contained additional 5'-terminal non-complementary (to template) 
nucleotides, specifying a r.e. site. The eDNA was thus tailored to contain a Bam HI r.e. site at each 
termini. This greatly facilitated the eventual cloning of the eDNA fragment and had the added 
advantage that only molecules containing the r.e. site at both termini, were efficiently ligated to form 
functional recombinant plasmids. 
The PCR product was analysed by agarose gel electrophoresis (Fig 3.2). Amplification yielded a 
major discrete DNA band of approximately 1.6 kb in length (lane c) when compared with the size 
marker (lane 2), which was in agreement with the length of the originally cloned fragment. The DNA 
fragment was purified from excess primers and unincorporated dNTP's, by excising the band from 
the gel and purifying it by the Geneclean™ procedure. After restriction with Bam HI, the tailored 
and amplified DNA fragment was ligated into the Bam HI site of pUC13 (Yanisch-Perron, 1985). The 
ligation mixture was used to transform competent E. coli JM 1 05 (Yanisch-Perron, 1985) cells to 
ampicillin resistance. On_. Amp/X-gai/IPTG plates, approximately 33% of the colonies were white, 
indicating the presence of recombinant plasmids. Five of these colonies were picked, the plasm ids 
extracted, digested with Bam HI and subjected to agarose gel electrophoresis (Fig. 3.3). Two did 
not contain a recombinant plasmid (lanes d and e) and were ignored. In the other cases, plasmids 
had incorporated a Bam HI fragment of the apparent correct size when compared with linearised 
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a b c 
Agarose gel analysis of the PCR product after removal of the GC-tails (c). Pst I 
digested p73 (b), which yielded the vector and the BTV4 VP5 gene insert. was 
included as a control and pAT153/Hinf I was used as a size marker. 
a b c d e f 
Agarose gel electrophoretic analysis of BamHI digested recombinant plasmids after 
ligation with the tailored VP5-gene (lanes b-f). Linearised pUC13 vector DNA (lane 
a) was included as a control. 
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3.4.2 Sequencing strategy 
It has been reported that Taq polymerase may have an overall error frequency of 0.25% in typical 
amplification reaction (Saiki eta/., 1988). Sequencing was thus undertaken not only to extend 
current knowledge of sequences of the VP5-genes of different serotypes of BTV (BTV4 VP5 
sequence is not yet known), but also to confirm that the open reading frame (ORF) had not been 
disturbed by the PCR reaction. An ORF is essential for further expression studies. Sequencing 
would also confirm that homopolymer tails had indeed been removed. 
The pUC13 vector (Yanish-Perron, 1985) contains the M13 multiple cloning site (MCS) which 
facilitates the use of the M 13 forward and reverse primers for sequencing purposes. Because the 
gene to be sequenced is approximately 1.6 kb in length, sequencing could not be performed from 
these primers alone (approximately 400bp can be sequenced from a single primer). The MCS offers 
a series of r.e. sites which are situated close to each other to form a so called cloning •casette• 
which is very convenient f.or the purpose of subcloning. By subcloning two regions of the VP5-gene 
and with the using custom made primers that were synthesised as the sequencing progressed, the 
complete nucleotide sequence was determined. 
3.4.3 Preparation of subclones 
Sequencing of approximately 350 nucleotides (nt) of each terminus of the cloned VP5-gene in 
pWF1 with the M13 forward and reverse primers, verified that tailoring had been sucessful. 
Homopolymer tails were removed and replaced by the Bam HI r.e. site. Restriction enzyme sites 
in these terminal regions that could be used for further subcloning, were identified using the 
Microgenie computer sequencing programme. The first subclone, pWF2, was constructed by 
excising a Hind Ill fragment of 180 bp in length from the 3' -terminus of the cloned gene and 
religating the plasmid. This made sequencing of nucleotides 11 00-1400 possible. The other 
subclone, pWF3, was constructed by excising a Pst 1/Sph I fragment from pWF1, purifying it using 
the Geneclean TM procedure and ligating it into the mulitiple cloning site of pUC18 (yanisch-Perron, 
1985) by forced cloning. In this way, 300 bp of the 5' -terminus of the cloned VP5-gene was deleted 
and sequencing of nucleotides 300 to 570 was accomplished. Sequencing of the remaining 
nucleotides was accomplished by using primers OP39 (for sequencing of nts 570-850) and OP31 
(for sequencing of nts 850-11 00). A diagram illustrating the constructed subclones and primers is 
given (Fig. 3.4), showing the manner in which the cloned VP5-gene was spanned for determination 
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Sublones constructed and primers used for the purpose of sequencing the cloned 
BTV4 VP5-gene. 
88 
of its nucleotide sequence. Sequencing was performed in only one direction, i.e. on either the ( +) 
or the (-) strand of the cloned DNA, depending on the primer used. 
3.4.4 The complete nucleotide sequence of the VP5-gene of SA-BTV4 
The complete nucleotide sequence of the BTV4 VP5-gene in its coding (mANA) sense is presented 
in Fig. 3.5, with the predicted amino acid sequence indicated below it. The VP5-gene segment is 
1638 base pairs in length. The coding·strand has a calculated base composition of 23.2% U, 32.0% 
A, 17.6% C, 27.2% G with a AT content of 55.2%. The gene contains a single long open reading 
frame stretching from nts 30 to 1607. The first 28 nts at the 5'-terminus and 31 nts at the 3'-
terminus represents non-coding sequences. The 5'- and 3'- termini contain the characteristic 
consensus sequences of orbivirus RNA segments, namely 5'-GTTAAA ... and ... ACTTAC-3' 
(underlined in Fig. 3.5). The open reading frame codes for a 526 amino acid protein. The protein 
of BTV4 has aM, of 59 274 Da, similar to that of VP5 of BTV10, which is 59 163 Da (Purdy eta/., 
1986). It contains 3 cystein residues at positions 152, 315 and 383. The amino acid (aa) 
composition of VPS (summarised in table 3.1), shows that the most abundant aa is glutamic acid 
while few tryptophan residues are present. The protein is also rich in certain non-polar aa such as 
alanine and isoleucine. It contains 15.4% acidic and 13.1% basic amino acids. 
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*** ' 10 20 30 40 50 60 70 80 90 100 110 
5-~AGTATTCTCCTACTCGCAGAAGATGGGGAAGATAATTAAATCGCTAAGTAGATTTGGAAAGAAAGTTGGAAACGCATTGTCGTCAAACACAGCGAAGAAAATTT 
MetGlylysllellelysSerleuSerArgPheGlylyslysValGlyAsnAlaleuSerSerAsnThrAlalyslyslleT 
120 130 140 150 160 170 180 190 200 210 220 
ATTCAACTATTGGGAAAGCAGCGGAACGTTTTGCTGAAACGGAGATCGGTGCGGCGACAATAGATGGGTTGGTGCAGGGTAGCGTTCATTCCATAATCACAGGTGAATCG 
yrSerThrlleGlylysAlaAlaGluArgPheAlaGluThrGlulleGlyAlaAlaThrlleAspGlyLeuValGlnGlySerValHisSerllelleThrGlyGluSer 
230 240 250 260 270 280 290 300 310 320 330 
TATGGAGAGTCAGTTAAACAGGCAGTTCTTCTCAACGTGTTAGGTACAGGTGAAGAGTTACCAGATCCACTGAGCCCTGGCGACCGTGGCATGCAAACGAAAATAAAGGA 
TyrGlyGluSerVallysGlnAlaValleuleuAsnValleuGlyThrGlyGluGluLeuProAspProleuSerProGlyAspArgGlyMetGlnThrlysllelysGl 
340 350 360 370 380 390 400 410 420 430 440 
STTGGAAGATGAGCAGCGGAATGAGCTTGTCCGATTGAAATACAATAAAGAGATAACAAAAGAGTTTGGGAAGGAGCTAGAAGAAGTGTACGATTTCATGAATGGCGAGG 
~LeuGluAsoGluGlnArgAsnGluleuValArgleulysTyrAsnlysGlulleThrlysGluPheGlylysGluleuGluGluValTyrAspPheMetAsnGlyGluA 
450 460 470 480 490 500 510 520 530 540 550 
CGAAAGAGGAGGAAGTGGTTCAGGAACAATACTCAATGCTATGCAAAGCGGTAGATTCATATGAGAAAATATTAAAAGCAGAGGACTCGAAAATGGGAATATTAGCACGC 
lalysGluGluGluValValGlnGluGlnTyrSenMetleuCyslysAlaValAspSerTyrGlulyslleleulysAlaGluAspSerlysMetGlylleleuAlaArg 
560 570 580 590 600 610 620 630 640 650 660 
SCATTGCAGCGGGAGGCTTCAGAGAGAAGTCAAGATGAAATCAAAATGGTGAAGGAGTACAGACAGAAGATTGATGCGCTTAAAAATGCGATCGAGATTGAACGAGACGG 
~~aleuGlnArgGluAlaSerGluArgSerGlnAspGluilelysMetValLysGluTyrArgGlnlyslleAspAlaleulysAsnAlalleGlulleGluArgAspGl 
670 580 690 700 710 720 730 740 750 760 770 
AATGCAGGAGGAGGCGATCCAGGAGATTGCCGGAATGACCGCTGACGTCTTAGAGGCGGCATCGGAGGAGGTGCCATTAATCGGCGCAGGTATGGCCACAGCTGTAGCGA 
y;~etGlnGluGiuAlaiieGlnGluileAlaGlyMetThrAlaAspValleuGluAlaAlaSerGluGluValProleuileGlyAlaGlyMetAlaThrAlaValAlaT 
. 780 790 800 810 820 830 840 850 860 870 880 
CCGGTAGGGCGATAGAAGGCGCATATAAATTGAAGAAGGTCATAAACGCGTTAAGTGGGATTGATTTATCGCATATGAGGAGTCCGAAGATTGAACCCACTATCATCGCC 
~rGlyArgAlaileGluGlyAlaTyrlysleulyslysVali1eAsnAlaleuSerGlyileAspleuSerHisMetArgSerProlysileGluProThri1eileAla 
890 900 910 920 930 940 950 960 970 980 990 
ACGACATTGGAGCATCGATTTAAAGAGATACCGGACGAGCAGCTGGCGGTAAGTGTTTTGAATAAAAAGACAGCGGTAACTGATAACTGCAATGAGATCGCGCATATCAA 
ThrlhrleuGluHisArgPhelysGluileProAspG1uGlnleuAlaValSerValleuAsnlyslysThrAlaValThrAspAsnCysAsnGluileAlaHisilely 
1000 1010 1020 1030 1040 1050 1060 1070 1080 1090 1100 
"CAAGAGATATTACCAAAGTTTAAACGGATTATGGATGAGGAGAAGGAGATTGAAGGAATAGAGGATAAAGTGATTCATCCGCGTGTGATGATGAGGTTCAAAATTCCTA 
sSinGluiieLeuProlysPhelysArgileMetAsoGluGlulysGluileGluGlyileGluAsplysValileHisProArgValMetMetArgPhelysileProA 
1110 1120 1130 1140 1150 1160 1170 1180 1190 1200 1210 
S4ACGCAGCAACCGCAAATCCACATTTATGCAGCCCCCTGGGATTCTGATGATGTGTTTTTCTTTCATTGCGTTTCACACCATCATCGGAACGAATCTTTTTTCCTGGGA 
rglhrGlnGinProGlnileHisileTyrAlaAlaProTrpAsoSerAsoAspValPhePhePheHisCysValSerHisHisHisArgAsnGluSerPhePheleuGly 
1220 1230 1240 1250 1260 1270 1280 1290 1300 1310 1320 
~ITGATCTAGGAATCGATGTCGTTCACTTTGAAGATTTAACCAGCCATTGGCACGCATTGGGACTAGCGCAAGAGGCGAGCGGGCGTACGTTAACGGAGGCGTATCGTGA 
;heAsoleuG1yi1eAsoValValHisPheG1uAspleuThrSerHisTrpHisA1aLeuGlyLeuA1aGlnGluAlaSerGlyArgThrleuThrGluAlaTyrArgG1 
-330 1340 1350 1 360 1 370 1 380 1390 1400 141 0 1420 1430 
STTTCTCAATTTATCAATTTCAAGCACATATAGCAGCGCTATACATGCGAGGCGTATGATTAGGTCACGAGCAGTACACCCAATTTTTCTAGGATCGATGCACTACGATA 
~~~eLeCJAsnLeuSerileSerSerThrTyrSerSerAlai1eHisAlaArgArgMetileArgSerArgAlaVa1HisProilePheleuGlySenMetHisTyrAspi 
1 !.110 1450 1460 1470 1480 1490 1500 1510 1520 1530 F .• 
~TACGTATGAAGCTTTGAAAAACAACGCGCAGAGAATAGTCTATGATGAGGAACTGCAAATGCATATTCTGAGGGGACCTTTGCACTTTCAGCGTCGAGCCACTCTGGG~ 
·elhrTy~GiuAlaLeulysAsnAsnA1aGlnArgileValTyrAspGluG1uleuGlnMetHisileLeuArgG1yProLeuHisPheGlnArgArgAlaThrleuG1y 
*** -,~so 1s5o 1570 1580 1590 ~soo 1610 152o i630 
:;CGTTGAAA TTTGGAGTT AAAA T A TT AGGCGA TAAAA TTGA TGTTCCCCTCTTCTT ACGAAA TGCA TGAACGCAGCGAGGGAGAAGCTT AC~-3' 
:·aLeuLys?heGlyValLysiieLeuGlyAsplysileAsoValProLeuPheleuArgAsnAla 
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Table 3.1 The amino acid composition of the SA BTV4 VP5 protein. 
AMINO ACID NO OF RESIDUES % OF SEQUENCE 
Alanine 46 8.7 
Arginine 29 5.5 
Asparagine 16 3.0 
Aspartic acid 26 4.9 
Cysteine 3 0.6 
Glutamine 20 3.8 
Glutamic acid 55 10.5 
Glycine 33 6.3 
Histidine 18 3.4 
Isoleucine 46 8.7 
Leucine 44 8.4 
Lysine 40 7.6 
Methionine 16 3.0 
Phenylalanine 19 3.6 
Proline 15 2.9 
Serine 32 6.1 
Threonine 23 4.4 
Tryptophane 2 0.4 
Tyrosine 14 2.7 
Valine 29 5.5 
Acidic (Asp+Giu) 81 15.4 
Basic (Arg+ Lys) 69 13.1 
Aromatic (Phe+ Trp+ Tyr) 35 6.7 
Hydrophobic (Aromatic + 
lie+ Leu + Met +Val) 170 32.3 
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3.5 DISCUSSION 
A cloned DNA copy of dsRNA gene VP5 (SA-BTV serotype 4) was successfully tailored by utilising 
the Polymerase Chain Reaction in a method described by Dennis (1990). This involved removal of 
the G/C homopolymeric flanking sequences from the gene, a consequence of the original cloning 
strategy. Furthermore a BamHI site was incorporated immediately adjacent to both the 5'- and 3'-
terminal VP5-gene ends, _which made cloning of the tailored product into the plasmid vector pUC13 
possible. 
The complete nucleotide sequence of this tailored VP5-gene was then determined, although not 
fully in both directions, i.e. on both cloned strands. From the sequence data, it is apparent that a 
full-length copy of the gene had been retained and cloned after tailoring, since the conserved 
sequences at the 5'- and 3'- termini were still present (Mertens and Sanger, 1985). It was also clear 
that the polymerase chain reaction had not resulted in mutations which disturbed the ORF, as it 
was of the same length as that previously reported for VP5 OAF's (e.g. Purdy eta/., 1896, Wade-
Evans eta/., 1988). The gene is 1638 bp in length and encodes a protein of 526 amino acids. 
The full length VP5-gene of the United States isolates BTV1 0 (Purdy eta/., 1986), BTV2 (Hirasawa 
and Roy, 1990) and BTV13 (Oldfield et al., 1991), the South African isolate BTV1 (Wade-Evans et 
a/., 1988), the Australian isolate BTV1 (Gould and Pritchard, 1988) and a related Orbivirus, namely 
EHDV-1 (ltawa eta/., 1991) has been cloned and sequenced. A comparison of the nucleotide 
sequences (Fig. 3.6) as w.ell as the predicted amino acid sequences (Fig 3. 7) of all these serotypes, 
including that of BTV4 VP5, is presented. 
The VP5-gene of SA-BTV4 is the same length than that of US-BTV10 (1638 bp), which is three 
nucleotides longer than that of US-BTV2 and both isolates of BTV1 (from South Africa and 
Australia), with a length of 1635 bp. It is one nucleotide longer than that of US-BTV13 (1637 bp) and 
five nucleotides shorter than the VP5-gene of EHDV-1 (1340 bp). 
The alignment of the predicted VP5 amino acid sequence (Fig 3. 7) demonstrates the close similarity 
of all these proteins. In the case of the bluetongue serotypes, no gap is required for maximum 
homologous allignment, while allignment of the EHDV-1 protein requires only three gaps. The VP5 
proteins of all of the BTV serotypes determined thus far are 526 aa in length, in contrast to the VP5 
protein of EHDV-1, which contains 527 aa. All of the VP5 proteins contain a conserved cysteine 
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of disulfide bridges for protein structure. Oldfield et a/., 1991 commented on the importance of a 
conserved glycine residue, identified at the amino acid terminus of VP5 following the starting 
methionine residue, which may be involved in myristoylation of this terminus. The fact that this 
residue is also found in VP5 of BTV4 gives further weight to this proposal. Gould and Pritchard,1988 
identified 4 major conserved amino acid regions (aa 1-112, 190-273, 361-420 and 478-515) in VP5 
linked by 3 variable regions (aa 137-189, 280-333 and 410-475). These assignments are also 
applicable to BTV4 VP5. 
The percentage nucleotide and amino acid similarities of VP5-genes of different Orbiviruses is 
presented in Table 3.2. The top row shows the nucleotide and the bottom row the amino acid 
similarities. The proteins of the bluetongue serotypes were much more conserved than their 
corresponding genes. In contrast, the proteins of EHOV in comparison with the bluetongue 
serotypes had approximately the same percentage of conservation as their corresponding genes. 
The overall direct aa similarities between the VP5 proteins of the bluetongue serotypes varied 
between 72% and 95% while the VP5 protein of EHDV was approximately 60% homologous to that 
of the bluetongue serotypes. It was clear that VP5 is not necessarily more conserved within 
serotypes (between SA-BTV1 and AUS-BTV1) than between serotypes. Indeed, the highest 
similarities occured between SA-BTV4 and US-BTV1 0 (80.2% homologous at nt level, 95.2% at aa 
level) and US-BTV2 and AUS-BTV1 (78.2% homologous at nt level, 90.3% at aa level), whereas SA-
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COMPARISON OF THE NUCLEIC ACID I PROTEIN SEQUENCE SIMILARITIES OF 
VP5 OF DIFFERENT ORBIVIRUS SEROTYPES 
US-BTV~ AUS-BTV1 SA-BTV1 US-BTV13 EHDV1 L 
69.1 68.4 68.5 71.7 63.3 SA-BTV4 
77.7 75.9 73.2 81.0 62.1 
68.6 68.0 68.3 72.3 61.3 US-
78.0 76.3 73.8 81.8 62.4 BTV10 
I 78.2 76.2 68.5 61.9 US-BTv2. 90.3 85.7 75.7 61.8 
~ 
76.9 68.9 62.1 AUS-
88.6 75.3 62.1 BTV1 






LUMPY SKIN DISEASE VIRUS PROTEIN SYNTHESIS 
4.1 INTRODUCTION 
The potential of vaccinia virus 0N) to serve as a vector for live recombinant vaccines is widely 
recognised. Several drawbacks are associated with the use of W (literature review, 1.6.2). For 
example its lack of species specificity is a major concern. This has prompted research on viruses 
which have a limited host-range, hence preventing spread to unintended species. The present 
study is part of a general programme to develop lumpy skin disease virus (LSDV) as a recombinant 
vector for use in veterinary medicine, since it has a host-range restricted to cattle, sheep and goats. 
As described in Chapter two, approximately 50% of the LSDV genome has been cloned. In order 
to exploit LSDV as an expression vecor of foreign genes, it is necessary to identify suitable 
promoters. Proteins and mANA of the virus which are expressed to high levels are indicative of 
strong promoters. To identify highly expressed proteins and mANA species, some basic knowledge 
of the growth cycle of LSDV is required. DNA accumulation and protein synthesis are parameters 
for viral growth. Very little is known about the characteristics of a LSDV infection, in stark contrast 
to that of a W infection. It is for example not known how soon after an LSDV infection viral DNA 
starts to replicate, when early protein synthesis starts and late protein synthesis ends and when 
progeny viruses are produced. Answers to these questions need to be established for a natural 
infection, before any deductions with regard to future recombinants could be made. 
It has been demonstrated that LSDV can be propagated in a variety of cell cultures (Weiss, 1968), 
including primary and established cells. In this study, the MDBK cell line was chosen for cultivation 
of LSDV for DNA isolation purposes (Chapter 2). It soon became apparent, however, that this virus 
behaved quite differently in these cells from other poxviruses that have been described. Most 
notably, CPE was not evident until approximately 4 days post infection (p.i.), in contrast to that of 
the orthopoxviruses such as vaccinia virus, for which CPE is readily observable within a few hours 
after infection (Moss, 1968). LSDV cytopathology remains localised and is limited to foci, with little 
immediate effect on the surrounding monolayer, whereas with an W infection, spread of the virus 
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soon destroys the monolayer. Low titres of LSDV (1 05 ffu/ml) in MDBK cells are characteristic and 
present a potential problem for animal trials. 
Consequently, the aim -of the work presented in this Chapter was to perform a preliminary 
investigation into the protein synthesis and the kinetics of LSDV in cell culture. To study the time 
course of accumulation of proteins in infected cells, newly synthesised proteins needed to be 
pulsed labelled with 35S-methionine at· various times post infection, followed by analysis by 50S-
polyacrylamide gel electrophoresis and autoradiography. An attempt was made to identify some 





The following radioisotope was purchased from Amersham International (UK): 
L-~S)-Methionine with a specific activity of 1326 Ci/mMol and a radioactive concentration of 
15mCi/ml {555MBq/ml). 
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4.3 METHODS 






Primary lamb testis (L T) cells were used for the propagation of virus and was obtained from Mr. 
P.A.M. Wege from the Virology Section, OVI. The LSDV vaccine strain Neethling, was used for the 
identification of proteins. Cell monolayers were infected with LSDV at an input multiplicity of 5 
ffu/cell in Eagles medium. Adsorption was allowed to continue for 2 hr at 37°C. The monolayers 
were then washed and maintained in Eagles medium at 37°C until such time that labelling of 
proteins commenced. 
4.3.2 Radiolabelling of proteins 
Confluent primary L T monolayers were washed twice with warm methionine-free Eagle's medium. 
Proteins were then labelled by the addition of (35S)-methionine (60pCi/1 x1 07 infected cells) 
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contained in methionine-free Eagle's medium. After 2 hr of incubation at 37°C, the medium was 
removed and the cells from each plate harvested using glass beads. Cells were pelleted at 800xg 
for 15 min, resuspended in PBS and pelleted again. The cells were then lysed by the addition of 
150~1 of sample buffer (0.2% SDS, 5% glyserol, 0.2% /3-ME, 15% urea, 50mM EDTA and 80mM Tris-
HCI pH 8. 7) and stored at -70°C prior to electrophoresis. 
4.3.3 Gel electrophoresis and autoradiography 
50S-polyacrylamide gel electrophoresis (SDS-PAGE) of LSDV proteins was carried out using the 
discontinuous gel system as described by Laemmli (1 970). The acrylamide:bis acrylamide ratio 
' 
used was 30 : 0.8 and 15% polyacrylamide seperating gels (13cm x 15cm x 1.5mm) were used. The 
gels were polymerised in a buffer containing 0.375M Tris-HCI pH 8.8, 0.1% SDS, 0.04% ammonium 
persulphate and 15~1 T~MED per 30ml of gel. A 5% stacking gel (4cm x 15cm x 1.5mm) was 
polymerised in a buffer containing 0.125M Tris-HCI pH 6.8, 0.1% SDS, 0.06% ammonium 
persulphate and 15~1 TEMED per 12ml of gel. The running buffer consisted of 0.1 M Tris-HCI pH 
8.9, 60mM glycine and 1% SDS. Before electrophoresis, samples were mixed with 2x loading buffer 
(0.275M Tris-HCI pH 6.8, 0. 7M /3-ME, 2% SDS, 10% glycerol and 0.001% Bromophenol blue as dye 
marker) and denatured by incubation at 90°C for 5 min. Electrophoresis was carried out using the 
mini-gel Hoefer electrophoresis system, applying a current of 150V for either 2 or 3.5 hr. After 
electrophoresis, the gels were stained for 15 min in a solution containing 0.2% Serva blue, 50% 
methanol and 10% acetic acid and destained at 60°C in 4% acetic acid. Gels were then dried and 
autoradiographed overnight. 
4.3.4 Treatment with cytosine arabinoside 
Cytosine arabinoside (CAR), an inhibitor of DNA synthesis was added to cell monolayers at a 
concentration of 25~g/ml. This inhibited the late virus stage from progressing. The drug was added 
to infected cells after ad$orption of viruses had occured. 
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4.4 RESULTS 
4.4.1 Identification of LSDV proteins 
Before experiments concerning viral protein kinetics or influence of inhibitors on protein synthesis 
could be performed, the presence of LSDV-specific proteins in infected cells needed to be 
demonstrated. LSDV infected cells were radio-actively labelled for a 4 hr labelling period, 
commencing at two different times post infection, namely at 24 hr and 42 hr p.i. After the labelling 
period, cells were harvested and lysed to yield a total cell-extract. The patterns of 35S-methionine 
incorporated polypeptides of uninfected (control) and LSDV-infected cells were analysed on 
polyacrylamide gels and compared. Gels were electrophoresed for either 3.5 hr (Fig 4.1 A) or 2 hr 
(Fig 4.1 B) , for the detection of both large and small polypeptides. The autoradiographs showed 
a complex pattern of bands which was, nevertheless, highly reproducible from experiment to 
experiment. 
Several polypeptide bands were detected in infected cell samples that were unique and differed 
from polypeptides found in the uninfected cells, in mobility and hence in molecular weight. This 
suggested that they were virus specific. Of these, 18 of the most abundantly expressed viral 
proteins were identified and are indicated by a ( · ) in Fig. 4.1 A and 4.1 B. A summary of the 
proteins and their relative expressions as judged by eye, of band intensities, is given in table 4.1. 
A reference protein ( • Fig. 4.1) indicated that approximately the same amount of protein was 
loaded onto the gel in the case of Fig. 4.1 A. In Fig. 4.1 B, lane 2 contained slightly less protein, 
which was taken into account when table 4.1 was compiled. Densitometric scanning, which allows 
a more precise quantitation of bands, was not feasible in this case due to inadequate resolution 
of these gels and the vast number of protein bands that were present. 
Many of these proteins, e.g. proteins 2, 4, 10, 11 and 13 seemed to be synthesised in 
approximately the same amount at both times post infection. Some, however, notably 6, 7, 9, 12 
and 17 have declined after 40 hr. Because of incompetent host cell protein shut-down, as is evident 
from the continual host protein synthesis throughout the 44 hr labelling period, the protein pattern 
was rather complicated. It is most probable that many of the viral proteins were masked by cellular 
proteins and could therefore not be identified. LSDV did however have some effect on the host cell 
metabolism, since some of the host proteins declined as the infection progressed (indicated by a 
( o) in Fig 4.1 A and B) , when compared with the reference protein ( • ). 
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Figure 4.1 A Autoradiograph of total protein expression in LSDV-infected LT-cells. At 24 hr p.i. 
(lane 1) and 40 hr p.i. (lane 2 ) cells were labelled for 4 hr with 358-methionine. 
Samples were electrophoresed in a 15% polyacrylamide gel for 3.5 hr. Lane U 
represents an uninfected control sample. Molecular weights are indicated in 
kilodaltons. 
Putative viral proteins 
Reference protein • 
Cellular proteins that clearly declined as the infection progressed. o 
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Figure 4.1 B Autoradiograph of total protein expression in LSDV-infected LT-cells. At 24 hr p.i. 
(lane 1) and 40 hr p.i (lane 2) cells were labelled for 4 hr with 358-methionine. 
Samples were electrophoresed in a 15% polyacrylamide gel for 2 hr. Lane U 
represents an uninfected control sample. Molecular weights are indicated in 
kilodaltons. 
Putative viral proteins 
Reference protein • 
Cellular proteins that clearly declined as the infection progressed. o 
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Table 4.1 Relative expression of LSDV proteins as judged by eye, of band intensities of Fig. 
4.1 A and B. Labelling of proteins commenced for 4 hours at the times indicated. 
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4.4.2 Kinetics of LSDV protein expression 
The time course of polypeptide synthesis in infected cells was followed in experiments where 
infected cells were pulse-labelled for 2hr with 358-methio.nine at various times after infection, as 
indicated in Fig. 4.2 A and B. Cells were harvested after the labelling period and lysed. Samples 
of these total cellular extracts were then analysed by polyacrylamide gel electrophoresis and 
autoradiography. The total radiolabelled protein pattern of LSDV-infected cells at different times p.i., 
is presented in Fig 4.2 A and B. No virus-specific protein was detectable prior to 16 hr post 
infection. At that time 2 .. putative viral proteins were detected in minute amounts (Fig. 4.2 A). 
Between 20 and 40 hr post infection (Fig 4.2 B), other viral proteins became clearly evident and all 
proteins were synthesised in ever-increasing amounts throughout the labelling period. The 
continuation of host protein synthesis, which failed to decline significantly over the 40 hr period, 
may however mask viral protein synthesis that had commenced prior to 16 hr p.i. 
4.4.3 Identification of early and late LSDV proteins 
The proteins synthesised in cells infe.cted with poxviruses can be divided into two classes, as was 
demonstrated for vaccinia virus (Joklik eta/., 1967), i.e. early proteins being made before, and late 
proteins after virus DNA synthesis. To identify early and late LSDV proteins, cytosine arabinoside 
(CAR) was used· as an inhibitor of virus DNA synthesis. This inhibitor has been used for the 
identification of early and late viral proteins of other viruses, e.g. vaccinia virus (Holowczak and 
Joklik, 1967, Pennington, 1974) and swinepox virus (Massung and Moyer, 1991 b). The 
concentration of the drug used in this experiment (251-'g/ml) was reported to inhibit virus DNA 
synthesis in infected cells by 94% (Pennington, 1974). 
For identification of early proteins, CAR (251-'g/ml) was added to a cell monolayer upon infection 
with LSDV. At 18 hr p.i., these infected cells were labelled with 358-methionine for a period of 14 hr. 
CAR was included throughout the labelling period. For comparison, the late viral phase was 
analysed by infecting a cell monolayer with LSDV, with no addition of CAR and labelling it at 40 hi" 
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Figure 4.2 A and B Autoradiographs of protein kinetics in LSDV-infected LT-cells. At the times 
indicated, cells were pulsed-labelled for 2 hr with 358-methionine. Samples 
were electrophoresed in 15% polyacrylamide gels for 2 hr. Lane U 
represents an uninfected control sample. Molecular weights are indicated 
in kilodaltons. 
Putative viral proteins are indicated by ( · ) . 
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An autoradiograph of results obtained is shown in Fig. 4.3. Three classes of proteins could be 
distinguished in the infected cell samples (Fig. 4.3, lanes 3 and 4) namely : 
1. those which were present in samples both treated and untreated with CAR ( ..... ), indicative 
of early proteins present in both the early and late virus phases. 
2. those which were present only in the sample treated Wit CAR ( • ), indicative of exclusively 
early proteins. 
3. those which were present only in the sample not treated with CAR ( * ), indicative of 
late proteins. 
Differences between the protein profiles of the CAR-treated and -untreated LSDV-infected sample 
and the uninfected control samples, made identification of some early and late viral proteins 
possible. Eight early LSDV proteins were identified (indicated by • and - in Fig. 4.3, lanes 3 and 
4). Of these, five (- ) occured in both the CAR-treated (containing only early proteins, lane 3) and 
untreated (containing early and late proteins, lane 4) samples. Three occured only in the CAR-
treated sample ( • lane 3). The fact that some of the early proteins were found in substantial 
amounts in the CAR untreated sample is indicative that at 40 hr p.i. unsynchronised replication is 
occuring. Some progeny virions are therefore already engaged in subsequent rounds of early 
protein synthesis, thus accounting for the presence of both early and late LSDV proteins. 
Only three late viral proteins ( * ), unique to the CAR-untreated infected sample, could be identified. 
It is unclear why no more could be distinguished. One explanation may be masking of other late 
proteins by the inefficient shut-down of host protein synthesis. 
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Figure 4.3 









-• * 14.3 
* 
Autoradiograph demonstrating the effect of cytosine arabinoside (251Jg/ml) on virus 
polypeptide synthesis. LSDV-infected CAR treated cells were labelled with 35S-
methionine for a 14 hr period, commencing at 18 hr p. i. (lane 3). CAR untreated 
infected cells were labelled for a 6 hr period at 40 hr p.i (lane 4) . Uninfected cells, 
both in the absence (lane 1) and presence (lane 2) of CAR was included as 
controls. Samples were electrophoresed for 2 hr in 15% acrylamide gels. Molecular 
weights are indicated in kilodaltons. 
- Putative early LSDV proteins, present in both the early and late viral phase. 
• Putative early LSDV proteins, present only in the early viral phase. 
* Putative late LSDV proteins, present only in the late viral phase. 
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4.5 Discussion 
Protein synthesis of various viruses, including vaccinia (Esteban and Metz, 1973) and swinepox 
viruses (Massung and Moyer, 1991 b) has been analysed by the 35S-methionine labelling of infected 
cells followed by SDS-polyacrylamide gel electrophoresis of the polypeptides. This preliminary study 
demonstrated that the method was also applicable for analyses of LSDV proteins. 
From autoradiographs, at least 18 35S-methionine labelled polypeptide bands were detected in 
LSDV-infected cells, that differed in mobility from those in uninfected cells. They were therefore 
assumed to be viral induced. The fact that some of these proteins may be processed host proteins, 
can, however, not be excluded. Only the major proteins were identified and although minor proteins 
were present, no attempt was made towards their identification. The number of polypeptides 
detected was limited by the single dimensional nature of the polyacrylamide gels and masking by 
host proteins. Doubtless many other LSDV components remain to be detected. If the whole of the 
Lumpy skin viral genome (approximately 143x1 06 bp) · encodes proteins, then some 180 
polypeptides of avarage molecular weight 40 000 D could be expressed. Such a large amount of 
polypeptides demonstrates the complex nature of LSDV. Elucidation of its biochemical aspects will 
be no small task. 
An interesting observation, that contributed to the small number of proteins detected, was the 
inability of LSDV to effectively shut off host protein synthesis. This differs markedly from reports of 
vaccinia virus infections, where host protein synthesis is rapidly and completely inhibited (Moss, 
1968}. A possible explanation in this case, may be the low number of inoculating Lumpy skin 
disease virions .(5 ffu/cell}, which was used since low titres of virus were obtained during cultivation 
(1 x1 05 ffu/cell). In the experiments where CAR was used as an inhibitor, host proteins were very 
prominent when compared to viral proteins, since CAR has no effect on host protein synthesis. The 
inefficient host shut-down may however be intrinsic to the virus itself. In a recent report on swinepox 
virus infections, host protein synthesis continued until between 24 and 32 hr post infection 
(Massung and Moyer, 1990b}. Growth characteristics of a LSDV infection, namely a CPE which is 
not evident until approximately 4 days p.i. and foci which remains localised, favour this explanation. 
These properties were also found for SPV, considered to be unusual among poxviruses, because 
of its slow DNA, RNA and protein kinetics (Massung and Moyer, 1991 b). 
Although the expression of host proteins complicated interpretation of autoradiographs, an attempt 
was made to examine the kinetics of LSDV protein synthesis. In this experiment infected cells were 
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pulse labelled with 35S-methionine at various times post infection. The first indication of viral protein 
expression was found at 16 hr p.i., when two viral proteins were detected in small amounts (Fig. 
4.2 A). By 24 hr p.i. the expression of others were clearly detected (Fig. 4.2 B). Protein synthesis 
for all detectable viral proteins continued to increase throughout the 42 hr labelling period of this 
experiment. Results of the initial experiment, where the presence of LSDV viral proteins were 
indicated (Fig. 4.1 A and B), demonstrated that expression of various proteins seemed to have 
declined when labelled from 42-46 hr p.i. (see table 4.1). This would imply that the peak of viral 
protein synthesis occured at approximately 42 hr p.i., whereafter it reached a plateau and started 
to decline. 
It is highly unlikely that early viral synthesis starts as late as 16 hr p.i. as these results indicated, 
when all previous reports of poxvirus synthesis is taken into account. For example, for vaccinia 
virus, early protein synthesis commences before 2 hr p.i. Late protein synthesis can already be 
observed at 4-6 hr p.i. (Moss and Salzman, 1968). The growth characteristics of LSDV however, 
differs starkly from vaccinia virus. It can be compared to swine pox virus (SPV) in that both are slow 
growers, with CPE being detected 4 days post infection. Analysis of SPV protein kinetics as had 
been performed in a stu~y (Massung and Moyer, 1991 b), allowed the detection of SPV proteins at 
24 hr p.i. lmmunoprecipitation in contrast, proved to be a more sensitive method, allowing SPV early 
proteins to be detected 4 hr p.i. and late proteins 10-12 hr p.i. (Massung and Moyer,1991b). LSDV 
protein kinetics therefore needs to be examined by immunoprecipitation before any conclusions can 
be drawn. 
A preliminary investigation into the effect of a DNA inhibitor, cytosine arabinoside (CAR) on virus 
growth, which inhibits the late virus stage from progressing, allowed the detection of eight apparent 
early and three putative late LSDV proteins. Because only two times p.i. were investigated, no 
conclusion on length of the early or late viral stages could be made. This experiment needs to be 
extended to include pulse chase labelling of viral proteins. The effect of CAR on protein synthesis, 
added to the LSDV infected cells for different lengths of time, therefore needs to be performed. It 
was interesting to note that many of the early proteins that were identified still occured in the late 
LSDV stage, i.e. in the 40-46 hr p.i. labelling period, where viral growth was not inhibited by CAR. 
If only one round of viral DNA replication occured at 40 hr p.i., these early proteins were therefore 
not processed and stayeo intact untill the late viral stage was reached. It is however more likely that 
these proteins are indeed processed as usual, but have accumulated at 40 hr p.i. because LSDV 
has gone through several cycles of replication. 
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One major consideration that might have influenced all of these results, is the relative low 
multiplicity of infection that was used in these experiments (5 ffu/cell). This low infectivety was used 
because of the low titres (5x1 a5 ffu/ml) of LSDV obtained in MDBK cells. Recently LSDV has been 
cultivated in Vero cells io our laboratory where it reached higher titres (5x1 as ffu/ml). This would 
allow for a higher input of infective viruses in future experiments. 
Although no concrete conclusions were reached in this study, some of the difficulties that have to 
be overcome in future research, have been pointed out. These include the fact that a higher input 
of infective viruses has to be used for a more complete host protein shut-down, stressing the need 
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